US20100120841A1 - Benzimidazole compound and pharmaceutical use thereof - Google Patents

Benzimidazole compound and pharmaceutical use thereof Download PDF

Info

Publication number
US20100120841A1
US20100120841A1 US12/449,874 US44987408A US2010120841A1 US 20100120841 A1 US20100120841 A1 US 20100120841A1 US 44987408 A US44987408 A US 44987408A US 2010120841 A1 US2010120841 A1 US 2010120841A1
Authority
US
United States
Prior art keywords
dihydro
benzimidazol
piperidin
lower alkyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/449,874
Other versions
US8877779B2 (en
Inventor
Masakazu Nakano
Masanori Minoguchi
Tokushi Hanano
Shin-ichiro Ono
Hideki Horiuchi
Koji Teshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Assigned to MITSUBISHI TANABE PHARMA CORPORATION reassignment MITSUBISHI TANABE PHARMA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HANANO, TOKUSHI, HORIUCHI, HIDEKI, MINOGUCHI, MASANORI, NAKANO, MASAKAZU, ONO, SHIN-ICHIRO, TESHIMA, KOJI
Publication of US20100120841A1 publication Critical patent/US20100120841A1/en
Application granted granted Critical
Publication of US8877779B2 publication Critical patent/US8877779B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to an invention of a compound which is an ORL-1 receptor agonist useful in the pharmaceutical field or a salt thereof, or a medicament containing the same.
  • ORL-1 opioid receptor-like 1 receptor
  • non-patent document 1 non-patent document 2
  • naloxone which is a nonselective opioid receptor antagonist
  • ORL-1 receptor is also expressed in peripheral organs such as bowel, spleen and the like, it is widely distributed mainly in the central nervous system, and highly densely expressed particularly in the cerebral cortex, hippocampus, hypothalamus, amygdala and spinal cord (see non-patent document 3, non-patent document 4).
  • Nociceptin is reported to be a peptide consisting of 17 amino acids, which plays an important role in the central nervous functions such as learning, memory, anxiety and stress (see non-patent document 7).
  • nociceptin receptor-knockout mouse quickly acquires learning in a water maze learning test as compared to normal mouse (wild-type) and that the knockout mouse shows enhanced long term potentiation (LTP) in hippocampus as compared to normal mouse (see non-patent document 9).
  • LTP long term potentiation
  • nociceptin-knockout mouse shows hypersensitivity to stress and impaired adaptability to stress as compared to normal mouse (see non-patent document 11).
  • nociceptin is considered to have a physiological action that functions defensively to anxiety and stress, and an ORL-1 receptor agonist is considered to potentially show an antianxiety action based on an action mechanism completely different from that of benzodiazepine compounds.
  • a compound having an ORL-1 receptor agonist activity is suggested to be useful for the treatment of mental disorder, neuropathy and physiological disorder, particularly, improvement of anxiety and stress disorder, melancholia, traumatic injury, loss of memory due to Alzheimer's disease or other dementia, symptom of epilepsy and convulsion, acute and/or chronic pain symptoms, relief of drug withdrawal symptoms including abstinence symptoms caused by cessation of abused drugs, alcohol abuse, control of water balance, Na + excretion, arterial blood pressure disorder, eating disorder such as obesity and anorexia, and circadian rhythm sleep disorder (see patent documents 1 to 9).
  • ORL-1 receptor agonist Ro64-6198 have been reported to have bioavailability (BA) of 4% (Proc. Natl. Acad. Sci. U.S.A. 97: 4938-4943, 2000).
  • the present inventors have intensively studied compounds having affinity for ORL-1 receptors, particularly compounds having an agonistic action on ORL-1 receptors, and found that compounds represented by the following formula (I) or salts thereof have a strong ORL-1 receptor agonistic action, have a superior metabolic stability and are expected to show high biological availability, which resulted in the completion of the present invention.
  • An object of the present invention is to provide an ORL-1 receptor agonist, which is strong and has high selectivity and superior metabolic stability as compared to known compounds.
  • the present invention provides the following.
  • the pharmaceutically acceptable salt encompasses acid addition salts with inorganic acid and organic acid, and salts with inorganic bases. Moreover, the present invention also encompasses a racemic mixture of compound (1), and a corresponding enantiomer thereof.
  • Compound (1) of the present invention has a superior ORL-1 receptor agonistic action, and is useful for the prophylaxis and/or treatment of diseases relating to ORL-1 receptor, for example, central nervous system diseases (e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism), acute and/or chronic pain symptom, arterial blood pressure disorder and eating disorders such as obesity and anorexia.
  • central nervous system diseases e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism
  • acute and/or chronic pain symptom e.g., arterial blood pressure disorder and eating disorders such as obesity and anorexia.
  • the compound of the present invention is superior in the metabolic stability and expected to have high bioavailability as compared to known compounds in the prior art, it is useful as a drug substance of medicaments.
  • FIG. 1 shows the ORL-1 receptor agonistic activity of the compounds of Examples 2, 4 and 8.
  • FIG. 2 shows the ORL-1 receptor agonistic activity of the compounds of Examples 79 and 80.
  • FIG. 3 shows the ORL-1 receptor agonistic activity of the compounds of Examples 104 and 110.
  • “Lower alkyl” means a straight or branched C 1-6 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, hexyl and the like, preferably a straight or branched C 1-4 alkyl, more preferably methyl, ethyl, propyl and isopropyl.
  • “Lower alkenyl” means straight or branched C 2-5 alkenyl, such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and the like, preferably a straight or branched C 2-4 alkenyl.
  • Halogen means chlorine, iodine, fluorine or bromine, preferably chlorine, fluorine or bromine, particularly preferably fluorine.
  • “Lower alkoxy” means a straight or branched C 1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, secondary butoxy, tertiary butoxy, pentyloxy, hexyloxy and the like, preferably a straight or branched C 1-4 alkoxy, particularly preferably methoxy.
  • Alkanoylamino means amino having C 2-6 alkanoyl, such as acetylamino, propionylamino, butyrylamino, pentanoylamino and the like, preferably acetylamino.
  • Cycloalkyl means C 3-7 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, preferably cyclopropyl.
  • “Saturated nitrogen-containing heterocycle formed by R 3 and R 4 in combination together with the adjacent nitrogen atom” means a 5- or 6-membered ring optionally further having 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom such as piperidine, pyrrolidine, morpholine, thiomorpholine, piperazine, methylpiperazine, thiazolidine, 2,4-dioxothiazolidine and the like, preferably piperazine, morpholine, pyrrolidine and 2,4-dioxothiazolidine, particularly preferably pyrrolidine and 2,4-dioxothiazolidine.
  • “Pharmaceutically acceptable salt” encompasses acid addition salts with inorganic acids and organic acids such as hydrochloric acid, oxalic acid, maleic acid, fumaric acid and the like, and salts with inorganic bases such as sodium, potassium, calcium, magnesium and the like.
  • the number of the substituents is preferably 1 to 3.
  • Preferable compound is a compound of the formula (I)
  • Particularly preferable compound is a compound of the formula (I),
  • a compound of the formula (II) is reductively aminated by a compound of the formula (III) to give a compound of the formula (I).
  • the compounds of the formula (II) and the formula (III) are known compounds, and the compound of the formula (II) can be produced by the method described in J. Chem. Soc., Perkin Trans 1, 1160, 1973, and the compound of the formula (III) can be produced by the method described in J. Med. Chem., 2001, 44, 3378 or Org. Lett., 2006, 8, 3311.
  • Reductive amination of a keto compound like the formula (II) using amine like the formula (III) is described in J. Org. Chem., 55, 2552-54, 1990.
  • the reaction by this method includes a reaction of ketone and amine in a solvent such as tetrahydrofuran (THF), methanol or ethanol or a mixture of appropriate alcohol and THF in the presence of Ti(IV)-isopropoxide and sodium cyanoborohydride.
  • THF tetrahydrofuran
  • methanol or ethanol or a mixture of appropriate alcohol and THF in the presence of Ti(IV)-isopropoxide and sodium cyanoborohydride.
  • the reaction temperature is about ⁇ 78 to 100° C., and the reaction time is several dozen min to 2 days.
  • L is a leaving group such as halogen, arylsulfonyloxy, alkylsulfonyloxy, arylphosphinyloxy, alkylphosphinyloxy and the like, and other symbols are as defined in the formula (I).
  • a compound of the formula (I) is obtained by a substitution reaction of the compound of the formula (III) and compound (X), which is induced from alcohol represented by the formula (IV), which is obtained by reducing ketone represented by the formula (II).
  • the substitution reaction of the compound of the formula (X) and the compound of the formula (III) is performed in N,N-dimethylformamide, dimethyl sulfoxide, pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, methanol, ethanol, diethyl ether etc., or a mixed solvent thereof, in the presence of an inorganic base such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide, sodium hydride and the like or an organic base such as triethylamine, diisopropylethylamine, pyridine, dimethylaminopyridine and the like.
  • the compound of the formula (VII) can be produced by the method described in WO03/082333 and using starting material (IV) as shown in the above scheme.
  • the compound of the formula (VII) is treated with phenylenediamine or pyridinediamine represented by the formula (VIII) to give the compound of the formula (IX), which is cyclized to give the compound of the formula (I-1) wherein R 1 is hydrogen.
  • Reductive amination of the keto compound of the formula (VII) with phenylenediamine or pyridinediamine of the formula (VIII) is performed in N,N-dimethylformamide, dimethyl sulfoxide, pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, methanol, ethanol, diethyl ether etc. or a mixed solvent thereof in the presence of metal complex hydride (e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, lithium borohydride, lithium aluminum hydride etc.).
  • metal complex hydride e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, lithium borohydride, lithium aluminum hydride etc.
  • the reaction temperature is about ⁇ 78 to 100° C., and the reaction time is several dozen min to 2 days.
  • Phenylenediamine or pyridinediamine of the formula (VIII), and the keto compound of the formula (VII) are known compounds.
  • phenylenediamine of the formula (VIII) can be produced by the method described in J. Org. Chem., 2001, 66, 919 or Org. Synth., 1943, 501
  • pyridinediamine can be produced by the method described in Org. Synth., 1964, 34.
  • the keto compound of the formula (VII) can be produced by the method described in Bioorganic & Medicinal Chemistry Letters, 1999, 9, 2343.
  • the compound of the formula (IX) produced by this reaction can be carbonylated or thiocarbonylated by a known method (see Bioorganic & Medicinal Chemistry Letters, 1996, 6, 1641, Chem. Pharm. Bull., 1989, 37, 962, Bioorganic & Medicinal Chemistry Letters, 1999, 9, 1537 and the like) to give the compound of the formula (I-1).
  • the compound of the formula (I-1) wherein R 1 is hydrogen is subjected to alkylation, alkenylation, phenylation, benzylation or acylation to give the compound of the formula (I).
  • the compound of the formula (I-1) wherein R 1 is hydrogen to can be subjected to alkylation, alkenylation, phenylation, benzylation or acylation by a conventional method, for example, in the presence of the corresponding alkyl halide, alkenyl halide, benzyl halide or acyl halide such as methyl iodide, allyl bromide, benzyl bromide, ethyl bromide, acetyl chloride, ethyl bromoacetate and the like.
  • This reaction is performed in the presence of metal hydride such as sodium hydride at a temperature of about ⁇ 78 to 100° C. for a reaction time of several dozen min to 2 days.
  • Compound (VII) can also be obtained by a reduction reaction via compound (XI) that can be produced by reacting the compound of the formula (II) with hydroxylamine, as shown in the following scheme.
  • ring A is as defined in the formula (I).
  • the compound of the formula (XI), which is a starting material compound, can be produced by a known method. For example, those described in “The Chemistry of Open-Chain Organic Nitrogen Compounds”, Vol 2, p 1 (1966) and “Organic Functional Group Preparations”, Vol 3, p 322 (1972) can be applied.
  • Reduction of oxime like the formula (XI) to amine can be performed by catalytic hydrogenation, Raney alloy-sodium hydroxide, diborane and sodium bis(2-methoxyethoxy)aluminum hydride and the like according to a known method.
  • oxime like the formula (XI) to amine can be performed by catalytic hydrogenation, Raney alloy-sodium hydroxide, diborane and sodium bis(2-methoxyethoxy)aluminum hydride and the like according to a known method.
  • Raney alloy-sodium hydroxide diborane and sodium bis(2-methoxyethoxy)aluminum hydride and the like according to a known method.
  • R 11 is lower alkyl-carboxyl
  • R 12 is lower alkyl-C(O)NR 3 R 4
  • R 3 , R 4 and other symbols are as defined in the formula (I).
  • a carboxylic acid compound represented by the formula (I-2) or a reactive derivative thereof and amine are reacted to give the compound of the formula (I-3).
  • a reactive derivative of the carboxylic acid compound includes acid halide such as acid chloride, acid anhydride, mixed acid anhydride formed from ethyl chloroformate and the like, ester such as methyl ester, ethyl ester and the like, and reactive derivatives produced from carbodiimide such as WSC.HCl (water soluble carbodiimide hydrochloride), DCC (dicyclohexylcarbodiimide) and the like.
  • the reaction is performed in an organic solvent such as N,N-dimethylformamide, dimethyl sulfoxide, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, toluene and the like.
  • organic solvent such as N,N-dimethylformamide, dimethyl sulfoxide, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, toluene and the like.
  • the reaction temperature is about ⁇ 78 to 100° C., and the reaction time is several dozen min to 2 days.
  • an organic base such as pyridine, triethylamine, diisopropylethylamine and the like is used as an acid scavenger.
  • an optically pure compound can be produced by converting the racemic mixture to an enantiomer component thereof. It is also possible to separate the sterically selective isomer from its racemic mixture at a suitable intermediate stage.
  • an enantiomer of the compound of the formula (I) can be produced using an optically active starting material (IV)′ by the method described in WO03/082333 as shown in the following scheme.
  • the obtained compound of the formula (I) is converted to a pharmaceutically acceptable salt.
  • Formation of salt is known per se, and is performed at room temperature by a well-known method. Not only salts with inorganic acid but also salts with organic acid are considered and, when the compound has a carboxyl group, salts with inorganic base and organic base are also considered. Acid addition salts such as hydrochloride, oxalate, fumarate, maleate and the like, sodium salt, potassium salt, calcium salt, magnesium salt and the like are examples of such salts.
  • the compound of the present invention can be administered orally and parenterally.
  • the dosage form includes tablet, capsule, granule, powder, injection, ointment, suppository and the like. These can be formulated by combining the compound of the present invention with various pharmaceutically acceptable additives such as excipient, bulking agent, lubricant, binder, disintegrant, coating agent, film-forming agent, base, solvent and the like, using conventional techniques.
  • the dose can be appropriately selected according to symptom, age, dosage form and the like, it is generally 0.1 to 5000 mg, preferably 1 to 1000 mg per day in the case of an oral preparation, which can be administered in one to several portions.
  • ⁇ -Tetralone (1.0 g) was dissolved in ethanol (20 ml), sodium borohydride (0.26 g) was added, and the mixture was stirred at room temperature for 30 min. 1N Hydrochloric acid (10 ml) was added to cease the reaction. Ethanol was evaporated, and the aqueous solution was extracted with chloroform. The extract was dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was dissolved in chloroform (10 ml), thionyl chloride (1.0 ml) was added, and the mixture was stirred with heating under reflux for 30 min. Chloroform and thionyl chloride were evaporated under reduced pressure, and the residue was dissolved in dimethylformamide (10 ml).
  • the crude product was dissolved in a mixed solvent (77 ml) of THF/water (10:1), triphenylphosphine (9.61 g) was added, and the mixture was heated under reflux for 1 hr. After cooling to room temperature, the solvent was evaporated, 1N hydrochloric acid (100 ml) was added to the residue, and unnecessary substances were removed by extraction with ethyl acetate. The aqueous phase was alkalified with potassium carbonate, and extracted with chloroform. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine.
  • N-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one (0.30 g) was dissolved in DMF (15 ml). Sodium hydride (35 mg, 60%) was added, and the suspension was stirred at room temperature for 30 min. Ethyl bromoacetate (0.1 ml) was added, and the mixture was stirred for 1 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate.
  • Example 75(2) and (3) In the same manner as Example 75(2) and (3) and using 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine (stereoisomer of Example 75(1)), the title compound was obtained as a white solid.
  • Example 76 In the same manner as Example 76 and using 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (stereoisomer of Example 75), the title compound was obtained as a white solid.
  • Example 76 In the same manner as Example 76 and using (1RS,3aSR)-1-[1- ⁇ (2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl ⁇ -1,3-dihydro-2H-benzimidazol-2-one (see WO2005/028466, Example 1), the title compound was obtained as a white solid.
  • Example 76 In the same manner as Example 76 and using (1RS,3aRS)-1-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (see WO2005/028466, Example 1), the title compound was obtained as a white solid.
  • the obtained (1RS,3aRS) form was resolved into (+) form and ( ⁇ ) form by optical resolution using HPLC.
  • Example 76 In the same manner as Example 76 and using 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • Example 85 In the same manner as Example 85 and using acetone instead of cyclopropanecarboxyaldehyde, the title compound was obtained as an oil.
  • Example 76 In the same manner as Example 76 and using 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as an oil.
  • Triphenylphosphine (2.7 g) was added, and the mixture was stirred at room temperature for 18 hr. The solvent was evaporated, 1N hydrochloric acid (200 ml) was added to the residue, and unnecessary substances were removed by extraction with ethyl acetate. The aqueous phase was alkalified with potassium carbonate, and extracted with chloroform. The extract was dried over sodium sulfate, and concentrated to give a amino form crude product. The crude amino form product (1.35 g) was dissolved in ethanol (15 ml).
  • the obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give (R)-N-[1-(5-fluoro-acenaphthen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.08 g).
  • the obtained diamine form (1.08 g) was dissolved in THF (10 ml), carbonyldiimidazole (600 mg) was added, and the mixture was stirred at room temperature for 2 hr.
  • the reaction mixture was poured into water, and the mixture was extracted with chloroform.
  • the extract was washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated.
  • the obtained residue was purified by silica gel column chromatography (chloroform/methanol) and recrystallized from a mixed solvent of ethyl acetate/diisopropylether to give the title compound (1.1 g) as a white solid.
  • 5-Fluoroacenaphthen-1-one (1.9 g) was dissolved in methanol (40 ml), sodium borohydride (470 mg) was added, and the mixture was stirred at room temperature for 40 min. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-fluoro-1-acenaphthenol (1.8 g). The obtained alcohol form (1.56 g) was dissolved in chloroform (12 ml).
  • the title compound is obtained according to the method of Example 128 and using 1-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • reaction mixture was poured into an aqueous potassium carbonate solution by small portions, during which unnecessary substances were dissolved in acetone), the mixture was extracted with chloroform, and the extract was dried over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by NH-coating silica gel column chromatography to give a crude product of the title compound.
  • the title compound is obtained according to the method of Example 125 and using 3-bromo-1-acenaphthenol.
  • the title compound is obtained according to the method of Example 104 and using 1-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • the title compound is obtained according to the method of Example 128 and using 1-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • the title compound is obtained according to the method of Example 104 and using 1-[1-(3-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • the obtained methoxy form was dissolved in methanol (25 ml), sodium borohydride (220 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 8-methoxy-1-acenaphthenol (5.6 g). The title compound (2.28 g) was obtained according to the method of Example 125 and using the obtained alcohol form.
  • the title compound is obtained according to the method of Example 128 and using 1-[1-(8-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • the title compound is obtained according to the method of Example 104 and using 1-[1-(8-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • the title compound is obtained according to the method of Example 103 and using 6-chloro-1-acenaphthenone.
  • the title compound was obtained as a white powder by preparing an acetone solution of an amorphous form obtained in the same manner as Example 142 and using (R)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and treating the acetone solution with 1.1 equivalents of fumaric acid.
  • the title compound (270 mg) was obtained as a yellow solid by treating a crude product obtained in the same manner as Example 145 and using 1-(bromomethyl)cyclopropane (310 mg) with 4N hydrochloric acid-ethyl acetate solution.
  • a [ 3 H]-nociceptin binding test was performed.
  • a test substance solution 50 ⁇ L having various concentrations
  • a receptor product solution 900 ⁇ L
  • a labeled ligand [ 3 H]-nociceptin 50 ⁇ L
  • the reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B. The filter was washed 3 times with ice-cooled 50 mmol/L HEPES buffer, and placed in a measurement vial.
  • a liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka).
  • the non-specific binding level was determined using an unlabeled ligand test compound A.
  • the binding inhibitory rate (%) and inhibitory constant (Ki value) were calculated according to the following calculation formula.
  • binding inhibitory rate (%) ⁇ 1 ⁇ ( B ⁇ N )/( T ⁇ N ) ⁇ 100
  • N non-specific binding level
  • T total binding level
  • IC 50 50% inhibitory concentration
  • L labeled ligand concentration
  • Kd dissociation constant of labeled ligand
  • a [ 3 H]-DAMGO binding test was performed.
  • a test substance solution 50 ⁇ L having various concentrations
  • a receptor product solution 900 ⁇ L
  • a labeled ligand [ 3 H]-DAMGO 50 ⁇ L
  • the reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B. The filter was washed 3 times with ice-cooled 50 mmol/L Tris/HCl buffer, and placed in a measurement vial.
  • a liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka).
  • the non-specific binding level was determined using an unlabeled ligand test compound A.
  • the binding inhibitory rate (%) and inhibitory constant (Ki value) were calculated according to the following calculation formula.
  • binding inhibitory rate (%) ⁇ 1 ⁇ ( B ⁇ N )/( T ⁇ N ) ⁇ 100
  • N non-specific binding level
  • T total binding level
  • IC 50 50% inhibitory concentration
  • L labeled ligand concentration
  • Kd dissociation constant of labeled ligand
  • a GTP ⁇ 35 S-binding test was performed.
  • a reaction buffer or a test substance solution 50 ⁇ L having various concentrations, a reaction buffer (for total binding) or a GTP ⁇ S solution (for non-specific binding, final concentration: 10 ⁇ mol/L) (50 ⁇ L), a membrane solution (850 ⁇ L) and a GTP ⁇ 35 S (Amersham Pharmacia Biotech) solution (final concentration: 100 ⁇ mol/L)(50 ⁇ L) were successively added to a polypropylene tube, and reacted at 30° C. for 60 min.
  • the reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B.
  • the filter was washed 3 times with ice-cooled 50 mmol Tris/HCl buffer (pH 7.4), and placed in a measurement vial.
  • a liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka).
  • the agonistic activity namely, GTP ⁇ 35 S bound (%) is shown by the following calculation formula.
  • GTP ⁇ 35 S bound (%) ⁇ ( B ⁇ N )/( A ⁇ N ) ⁇ 100
  • the compounds of Examples 2, 4, 8, 79, 80, 104 and 110 increased the proportion of GTP ⁇ 35 S bound in a concentration-dependent manner.
  • the compounds of Examples 2, 4, 8, 79, 80, 104 and 110 act as agonists for ORL-1 receptor.
  • compound of the present invention 10 mg crystalline cellulose 180 mg cornstarch 300 mg lactose 600 mg magnesium stearate 15 mg
  • the compound of the present invention lactose, cornstarch and crystalline cellulose were mixed and kneaded using polyvinylpyrrolidone K30 paste, and the mixture was passed through a 20 mesh sieve to give granules. After drying at 50° C. for 2 hr, the granules were passed through a 24 mesh sieve, mixed with talc and magnesium stearate, and tablet weighing 120 mg per tablet was produced using a pestle with diameter 7 mm.
  • Compound (1) of the present invention has superior metabolic stability and strong ORL-1 receptor agonistic action, and can be used for the prophylaxis and/or treatment of diseases relating to ORL-1 receptors, such as central nervous system diseases (e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism), acute and/or chronic pain symptom, arterial blood pressure disorder and eating disorders such as obesity and anorexia.
  • central nervous system diseases e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism
  • acute and/or chronic pain symptom e.g., acute and/or chronic pain symptom
  • arterial blood pressure disorder and eating disorders such as obesity and anorexia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I)
Figure US20100120841A1-20100513-C00001
wherein each symbol is as defined in the claims.

Description

    TECHNICAL FIELD
  • The present invention relates to an invention of a compound which is an ORL-1 receptor agonist useful in the pharmaceutical field or a salt thereof, or a medicament containing the same.
    • BACKGROUND ART
  • The ORL-1 (opioid receptor-like 1) receptor (see non-patent document 1, non-patent document 2) is a receptor found in 1994 as the fourth opioid receptor following δ, κ and μ receptors, and has about 60% homology of amino acid sequence with other opioid receptors. However, it is clearly different from other opioid receptors in that it is not bound with naloxone, which is a nonselective opioid receptor antagonist (see non-patent document 2). While ORL-1 receptor is also expressed in peripheral organs such as bowel, spleen and the like, it is widely distributed mainly in the central nervous system, and highly densely expressed particularly in the cerebral cortex, hippocampus, hypothalamus, amygdala and spinal cord (see non-patent document 3, non-patent document 4).
  • In 1995, endogenous ligands for ORL-1 receptors were sequentially identified by research groups in France and Switzerland, and named as nociceptin (see non-patent document 5) and orphanin FQ (see non-patent document 6). Nociceptin is reported to be a peptide consisting of 17 amino acids, which plays an important role in the central nervous functions such as learning, memory, anxiety and stress (see non-patent document 7).
  • To be specific, it has been reported that injection of a trace amount of nociceptin into hippocampus of rat induces a learning disorder in a water maze learning test (see non-patent document 8), and that nociceptin receptor-knockout mouse quickly acquires learning in a water maze learning test as compared to normal mouse (wild-type) and that the knockout mouse shows enhanced long term potentiation (LTP) in hippocampus as compared to normal mouse (see non-patent document 9). Hence, nociceptin is considered to suppressively act on the memory-learning function. In addition, it has been reported that administration of nociceptin to rat brain ventricle provides an antianxiety activity almost equivalent to that of diazepam in behavioral pharmacological tests such as conflict test, light/dark box test, elevated plus maze test and the like (see non-patent document 10). Furthermore, it has been reported that nociceptin-knockout mouse shows hypersensitivity to stress and impaired adaptability to stress as compared to normal mouse (see non-patent document 11). In other words, nociceptin is considered to have a physiological action that functions defensively to anxiety and stress, and an ORL-1 receptor agonist is considered to potentially show an antianxiety action based on an action mechanism completely different from that of benzodiazepine compounds.
  • From the foregoing, a compound having an ORL-1 receptor agonist activity is suggested to be useful for the treatment of mental disorder, neuropathy and physiological disorder, particularly, improvement of anxiety and stress disorder, melancholia, traumatic injury, loss of memory due to Alzheimer's disease or other dementia, symptom of epilepsy and convulsion, acute and/or chronic pain symptoms, relief of drug withdrawal symptoms including abstinence symptoms caused by cessation of abused drugs, alcohol abuse, control of water balance, Na+ excretion, arterial blood pressure disorder, eating disorder such as obesity and anorexia, and circadian rhythm sleep disorder (see patent documents 1 to 9).
      • non-patent document 1: FEBS Lett. 347:284-288, 1994
      • non-patent document 2: FEBS Lett. 341:33-38, 1994
      • non-patent document 3: Eur. J. Pharmacol. 340:1-15, 1997
      • non-patent document 4: Pharmacol. Rev. 53:381-415, 2001
      • non-patent document 5: Nature 377:532-535, 1995
      • non-patent document 6: Science 270:792-794, 1995
      • non-patent document 7: Br. J. Pharmacol. 129, 1261-1283, 2000
      • non-patent document 8: Eur. J. Neurosci. 9, 194-197, 1997
      • non-patent document 9: Nature 394, 577-581, 1998-14858, 1997
      • non-patent document 10: Proc. Natl. Acad. Sci. USA 94, 14854-10449, 1999
      • non-patent document 11: Proc. Natl. Acad. Sci. USA 96, 10444
      • patent document 1: JP-A-2000-26466
      • patent document 2: JP-A-11-228575
      • patent document 3: JP-A-10-212290
      • patent document 4: WO99/36421
      • patent document 5: WO98/54168
      • patent document 6: WO01/39775
      • patent document 7: WO00/06545
      • patent document 8: WO03/082333
      • patent document 9: WO05/028466
    DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention
  • The known ORL-1 receptor agonist Ro64-6198 have been reported to have bioavailability (BA) of 4% (Proc. Natl. Acad. Sci. U.S.A. 97: 4938-4943, 2000).
  • The present inventors have intensively studied compounds having affinity for ORL-1 receptors, particularly compounds having an agonistic action on ORL-1 receptors, and found that compounds represented by the following formula (I) or salts thereof have a strong ORL-1 receptor agonistic action, have a superior metabolic stability and are expected to show high biological availability, which resulted in the completion of the present invention.
  • An object of the present invention is to provide an ORL-1 receptor agonist, which is strong and has high selectivity and superior metabolic stability as compared to known compounds.
    • Means of Solving the Problems
  • Accordingly, the present invention provides the following.
  • [1] A compound represented by the formula (I)
  • Figure US20100120841A1-20100513-C00002
  • is one of
  • Figure US20100120841A1-20100513-C00003
    • m and n are the same or different and each is an integer of 1 to 3;
    • R1 is hydrogen,
      • lower alkyl,
      • lower alkenyl,
      • —C(O)-lower alkyl,
      • —C(O)O-lower alkyl,
      • —C(O)-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, lower alkyl-carboxyl,
      • lower alkyl-C(O)-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy,
      • lower alkyl-C(O)O-lower alkyl,
      • lower alkenyl-C(O)O-lower alkyl,
      • lower alkyl-O-lower alkyl,
      • lower alkyl-C(O)—NR3R4,
      • —S(O)2-lower alkyl,
      • —S(O)2-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy,
      • lower alkyl-S-lower alkyl,
      • lower alkyl-S(O)-lower alkyl,
      • lower alkyl-S(O)2-lower alkyl,
      • lower alkyl-S(O)—NR3R4,
      • lower alkyl-NR3R4,
      • lower alkyl-NR5—C(O)-lower alkyl,
      • phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, or
      • benzyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
    • R3 and R4 are the same or different and each is hydrogen, lower alkyl which is optionally substituted by C3-7 cycloalkyl, cycloalkyl or lower alkenyl, or R3 and R4 in combination optionally form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
    • R5 is hydrogen, lower alkyl or lower alkenyl;
    • R2 is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, nitro, amino or cyano;
    • Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, amino, alkanoylamino or cyano,
      • provided that when
  • Figure US20100120841A1-20100513-C00004
      • is (c), either Ra or Rb is a group other than hydrogen;
    • X is O or S;
    • Y is CH2, C(CH3)2, O, S, SO or SO2; and
    • Z is CH or N, provided that when
  • Figure US20100120841A1-20100513-C00005
      • is (b), m is 2, n is 2, Y is CH2 and X is O,
      • then R1 is a group other than hydrogen, lower alkyl, —C(O)— lower alkyl and —C(O)O-lower alkyl,
        or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
        [2] The compound of [1] wherein R2 is hydrogen and X is O, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
        [3] The compound of [1] wherein R1 is lower alkyl-C(O)—NR3R4 (one of R3 and R4 is hydrogen) or lower alkyl-C(O)—NR3R4 (R3 and R4 in combination form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy),
        or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
        [4] The compound of [1] which is selected from
    • 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-(1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-(4-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(2,3,3a,4,5,6-hexahydrobenzo[de]chromen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, and
    • 2-{3-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
      or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [5] A drug for the prophylaxis and/or treatment of a disease relating to an ORL-1 receptor, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [6] A drug for the prophylaxis and/or treatment of a central nervous system disease relating to an ORL-1 receptor, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [7] A drug for the prophylaxis and/or treatment of a central nervous system disease, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [8] A drug for the prophylaxis and/or treatment of a sleep disorder, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [9] A drug for the prophylaxis and/or treatment of alcoholism, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [10] A drug for the prophylaxis and/or treatment of drug addiction, comprising the compound (1) of [1], or a racemic is mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
      [11] A drug for the prophylaxis and/or treatment of anxiety and stress disorder, comprising the compound (1) of [1], or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
  • In the present specification, the pharmaceutically acceptable salt encompasses acid addition salts with inorganic acid and organic acid, and salts with inorganic bases. Moreover, the present invention also encompasses a racemic mixture of compound (1), and a corresponding enantiomer thereof.
    • EFFECT OF THE INVENTION
  • Compound (1) of the present invention has a superior ORL-1 receptor agonistic action, and is useful for the prophylaxis and/or treatment of diseases relating to ORL-1 receptor, for example, central nervous system diseases (e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism), acute and/or chronic pain symptom, arterial blood pressure disorder and eating disorders such as obesity and anorexia. Particularly, since the compound of the present invention is superior in the metabolic stability and expected to have high bioavailability as compared to known compounds in the prior art, it is useful as a drug substance of medicaments.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the ORL-1 receptor agonistic activity of the compounds of Examples 2, 4 and 8.
  • FIG. 2 shows the ORL-1 receptor agonistic activity of the compounds of Examples 79 and 80.
  • FIG. 3 shows the ORL-1 receptor agonistic activity of the compounds of Examples 104 and 110.
    •  BEST MODE FOR CARRYING OUT THE INVENTION
  • The definition of each symbol of the formula (I) is as follows. In the present specification, the definitions apply no matter whether the term is used alone or in combination.
  • “Lower alkyl” means a straight or branched C1-6 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl, tertiary butyl, pentyl, hexyl and the like, preferably a straight or branched C1-4 alkyl, more preferably methyl, ethyl, propyl and isopropyl.
  • “Lower alkenyl” means straight or branched C2-5 alkenyl, such as vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and the like, preferably a straight or branched C2-4 alkenyl.
  • “Halogen” means chlorine, iodine, fluorine or bromine, preferably chlorine, fluorine or bromine, particularly preferably fluorine.
  • “Lower alkoxy” means a straight or branched C1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, secondary butoxy, tertiary butoxy, pentyloxy, hexyloxy and the like, preferably a straight or branched C1-4 alkoxy, particularly preferably methoxy.
  • “Alkanoylamino” means amino having C2-6 alkanoyl, such as acetylamino, propionylamino, butyrylamino, pentanoylamino and the like, preferably acetylamino.
  • “Cycloalkyl” means C3-7 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, preferably cyclopropyl.
  • “Saturated nitrogen-containing heterocycle formed by R3 and R4 in combination together with the adjacent nitrogen atom” means a 5- or 6-membered ring optionally further having 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom such as piperidine, pyrrolidine, morpholine, thiomorpholine, piperazine, methylpiperazine, thiazolidine, 2,4-dioxothiazolidine and the like, preferably piperazine, morpholine, pyrrolidine and 2,4-dioxothiazolidine, particularly preferably pyrrolidine and 2,4-dioxothiazolidine.
  • “—C(O)—” means carbonyl.
  • “—NR5—C(O)— wherein R5 is as defined in the above-mentioned formula (I)” means an amide.
  • “—S(O)—” means sulfinyl.
  • “—S(O)2—” means sulfonyl.
  • “Pharmaceutically acceptable salt” encompasses acid addition salts with inorganic acids and organic acids such as hydrochloric acid, oxalic acid, maleic acid, fumaric acid and the like, and salts with inorganic bases such as sodium, potassium, calcium, magnesium and the like.
  • When the phenyl or the saturated nitrogen-containing heterocycle formed together with the adjacent nitrogen atom in the formula (I) is substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, the number of the substituents is preferably 1 to 3.
  • Preferable compound is a compound of the formula (I)
    • wherein R1 is hydrogen, —C(O)-lower alkyl, lower alkyl-carboxyl, lower alkyl-O-lower alkyl, lower alkyl-C(O)—NR3R4 or lower alkyl-NR3R4;
    • R3 and R4 are the same or different and each is hydrogen, lower alkyl which is optionally substituted by C3-7 cycloalkyl, or cycloalkyl, or R3 and R4 in combination optionally form, together with the adjacent nitrogen atom, a saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
    • R2 is hydrogen or halogen;
    • Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy, hydroxyl, trifluoromethyl, alkanoylamino or cyano, provided that when
  • Figure US20100120841A1-20100513-C00006
    • is (c), either Ra or Rb is a group other than hydrogen;
    • Y is CH2, C(CH3)2, O, S or SO2; and
      other symbols are as defined in the above-mentioned formula (I),
      provided that when
  • Figure US20100120841A1-20100513-C00007
      • is (b), m is 2, n is 2, Y is CH2 and X is O, R1 is a group other than hydrogen and —C(O)-lower alkyl.
  • Particularly preferable compound is a compound of the formula (I),
  • wherein
  • Figure US20100120841A1-20100513-C00008
  • is the following formula (a):
  • Figure US20100120841A1-20100513-C00009
    • R1 is hydrogen, —C(O)-lower alkyl, lower alkyl-carboxyl, lower alkyl-O-lower alkyl, lower alkyl-C(O)—NR3R4 or lower alkyl-NR3R4;
    • R3 and R4 are the same or different and each is hydrogen, lower alkyl or cycloalkyl, or R3 and R4 in combination optionally form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
    • R2 is hydrogen or halogen;
    • Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy, hydroxyl, trifluoromethyl, alkanoylamino or cyano;
    • Y is CH2, C(CH3)2, O, S or SO2; and
      other symbols are as defined in the above-mentioned formula (I).
  • For example, the following compounds can be mentioned: a compound selected from
    • 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-(1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-(4-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, and
    • 2-{3-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
      or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
  • Other particularly preferable compound is a compound of the formula (I),
  • wherein
  • Figure US20100120841A1-20100513-C00010
  • is the following formula (b):
  • Figure US20100120841A1-20100513-C00011
    • R1 is hydrogen, —C(O)-lower alkyl, lower alkyl-C(O)—NR3R4 or lower alkyl-NR3R4;
    • R3 and R4 are the same or different and each is hydrogen, lower alkyl which is optionally substituted by C3-7 cycloalkyl, or cycloalkyl, or R3 and R4 in combination optionally form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
    • R2 is hydrogen or halogen;
    • Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy or hydroxyl;
    • X is O;
    • Y is CH2 or O;
    • Z is CH; and
      other symbols are as defined in the above-mentioned formula (I),
      provided that when m is 2, n is 2 and Y is CH2, then R1 is a group other than hydrogen and —C(O)-lower alkyl.
  • For example, the following compounds can be mentioned: a compound selected from
    • 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-[1-(2,3,3a,4,5,6-hexahydrobenzo[de]chromen-6-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-[1-(2,3,3a,4,5,6-hexahydro-benzo[de]chromen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
    • 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 1-[2-(cyclopropylmethylamino)ethyl]-3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
    • 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-3-(2-isopropylaminoethyl)-1,3-dihydro-2H-benzimidazol-2-one,
    • 3-{3-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}propyl}thiazolidine-2,4-dione,
    • 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, and
    • 2-{3-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
      or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
  • Other particularly preferable compound is a compound of the formula (I),
  • wherein
  • Figure US20100120841A1-20100513-C00012
  • is the following formula (c):
  • Figure US20100120841A1-20100513-C00013
    • R1 is hydrogen, —C(O)-lower alkyl or lower alkyl-C(O)—NR4R5 (one of R4 and R5 is hydrogen) or lower alkyl-C(O)—NR4R5 (R4 and R5 in combination form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy);
    • R2 is hydrogen or halogen;
    • Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy, hydroxyl or cyano, provided one of Ra and Rb is a group other than hydrogen;
    • X is O; and
      other symbols are as defined in the above-mentioned formula (I).
  • For example, the following compounds can be mentioned: a compound selected from
    • 2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
    • 2-{3-[1-(5-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, and
    • (R)-2-{3-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
      or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
  • Compound of the formula (I) (unless otherwise specified, compounds of the formula (I), wherein
  • Figure US20100120841A1-20100513-C00014
  • is one of
  • Figure US20100120841A1-20100513-C00015
  • are included) can be prepared, for example, by the following methods.
  • Figure US20100120841A1-20100513-C00016
  • wherein each symbol is as defined in the aforementioned formula (I), provided that
  • Figure US20100120841A1-20100513-C00017
  • is not
  • Figure US20100120841A1-20100513-C00018
  • A compound of the formula (II) is reductively aminated by a compound of the formula (III) to give a compound of the formula (I). The compounds of the formula (II) and the formula (III) are known compounds, and the compound of the formula (II) can be produced by the method described in J. Chem. Soc., Perkin Trans 1, 1160, 1973, and the compound of the formula (III) can be produced by the method described in J. Med. Chem., 2001, 44, 3378 or Org. Lett., 2006, 8, 3311.
  • Reductive amination of a keto compound like the formula (II) using amine like the formula (III) is described in J. Org. Chem., 55, 2552-54, 1990. The reaction by this method includes a reaction of ketone and amine in a solvent such as tetrahydrofuran (THF), methanol or ethanol or a mixture of appropriate alcohol and THF in the presence of Ti(IV)-isopropoxide and sodium cyanoborohydride. The reaction temperature is about −78 to 100° C., and the reaction time is several dozen min to 2 days.
  • Figure US20100120841A1-20100513-C00019
  • wherein L is a leaving group such as halogen, arylsulfonyloxy, alkylsulfonyloxy, arylphosphinyloxy, alkylphosphinyloxy and the like, and other symbols are as defined in the formula (I).
  • A compound of the formula (I) is obtained by a substitution reaction of the compound of the formula (III) and compound (X), which is induced from alcohol represented by the formula (IV), which is obtained by reducing ketone represented by the formula (II). The substitution reaction of the compound of the formula (X) and the compound of the formula (III) is performed in N,N-dimethylformamide, dimethyl sulfoxide, pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, methanol, ethanol, diethyl ether etc., or a mixed solvent thereof, in the presence of an inorganic base such as potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydroxide, sodium hydroxide, sodium hydride and the like or an organic base such as triethylamine, diisopropylethylamine, pyridine, dimethylaminopyridine and the like. In addition, a catalytic amount to a small excess of sodium iodide, potassium iodide and the like may also be present. The reaction temperature is about room temperature to 200° C., and the reaction time is several min to 2 days.
  • Figure US20100120841A1-20100513-C00020
  • wherein each symbol is as defined in the formula (I).
  • The compound of the formula (VII) can be produced by the method described in WO03/082333 and using starting material (IV) as shown in the above scheme.
  • The compound of the formula (VII) is treated with phenylenediamine or pyridinediamine represented by the formula (VIII) to give the compound of the formula (IX), which is cyclized to give the compound of the formula (I-1) wherein R1 is hydrogen.
  • Reductive amination of the keto compound of the formula (VII) with phenylenediamine or pyridinediamine of the formula (VIII) is performed in N,N-dimethylformamide, dimethyl sulfoxide, pyridine, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, methanol, ethanol, diethyl ether etc. or a mixed solvent thereof in the presence of metal complex hydride (e.g., sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, lithium borohydride, lithium aluminum hydride etc.). The reaction temperature is about −78 to 100° C., and the reaction time is several dozen min to 2 days. Phenylenediamine or pyridinediamine of the formula (VIII), and the keto compound of the formula (VII) are known compounds. For example, phenylenediamine of the formula (VIII) can be produced by the method described in J. Org. Chem., 2001, 66, 919 or Org. Synth., 1943, 501, and pyridinediamine can be produced by the method described in Org. Synth., 1964, 34. The keto compound of the formula (VII) can be produced by the method described in Bioorganic & Medicinal Chemistry Letters, 1999, 9, 2343.
  • The compound of the formula (IX) produced by this reaction can be carbonylated or thiocarbonylated by a known method (see Bioorganic & Medicinal Chemistry Letters, 1996, 6, 1641, Chem. Pharm. Bull., 1989, 37, 962, Bioorganic & Medicinal Chemistry Letters, 1999, 9, 1537 and the like) to give the compound of the formula (I-1).
  • Figure US20100120841A1-20100513-C00021
  • wherein each symbol is as defined in the formula (I).
  • The compound of the formula (I-1) wherein R1 is hydrogen is subjected to alkylation, alkenylation, phenylation, benzylation or acylation to give the compound of the formula (I).
  • The compound of the formula (I-1) wherein R1 is hydrogen to can be subjected to alkylation, alkenylation, phenylation, benzylation or acylation by a conventional method, for example, in the presence of the corresponding alkyl halide, alkenyl halide, benzyl halide or acyl halide such as methyl iodide, allyl bromide, benzyl bromide, ethyl bromide, acetyl chloride, ethyl bromoacetate and the like. This reaction is performed in the presence of metal hydride such as sodium hydride at a temperature of about −78 to 100° C. for a reaction time of several dozen min to 2 days.
  • Compound (VII) can also be obtained by a reduction reaction via compound (XI) that can be produced by reacting the compound of the formula (II) with hydroxylamine, as shown in the following scheme.
  • Figure US20100120841A1-20100513-C00022
  • wherein ring A is as defined in the formula (I).
  • The compound of the formula (XI), which is a starting material compound, can be produced by a known method. For example, those described in “The Chemistry of Open-Chain Organic Nitrogen Compounds”, Vol 2, p 1 (1966) and “Organic Functional Group Preparations”, Vol 3, p 322 (1972) can be applied.
  • Reduction of oxime like the formula (XI) to amine can be performed by catalytic hydrogenation, Raney alloy-sodium hydroxide, diborane and sodium bis(2-methoxyethoxy)aluminum hydride and the like according to a known method. For example, those described in “Shin Jikken Kagaku Koza (Courses in Experimental Chemistry) vol. 14”, p 1339 (1978) can be used.
  • Figure US20100120841A1-20100513-C00023
  • wherein R11 is lower alkyl-carboxyl, R12 is lower alkyl-C(O)NR3R4, and R3, R4 and other symbols are as defined in the formula (I).
  • A carboxylic acid compound represented by the formula (I-2) or a reactive derivative thereof and amine are reacted to give the compound of the formula (I-3). A reactive derivative of the carboxylic acid compound includes acid halide such as acid chloride, acid anhydride, mixed acid anhydride formed from ethyl chloroformate and the like, ester such as methyl ester, ethyl ester and the like, and reactive derivatives produced from carbodiimide such as WSC.HCl (water soluble carbodiimide hydrochloride), DCC (dicyclohexylcarbodiimide) and the like.
  • The reaction is performed in an organic solvent such as N,N-dimethylformamide, dimethyl sulfoxide, dioxane, tetrahydrofuran, acetonitrile, chloroform, methylene chloride, dichloroethane, toluene and the like. The reaction temperature is about −78 to 100° C., and the reaction time is several dozen min to 2 days. Where necessary, an organic base such as pyridine, triethylamine, diisopropylethylamine and the like is used as an acid scavenger.
  • When the compound of the formula (I) synthesized as shown above is obtained as a racemate, an optically pure compound can be produced by converting the racemic mixture to an enantiomer component thereof. It is also possible to separate the sterically selective isomer from its racemic mixture at a suitable intermediate stage.
  • In addition, an enantiomer of the compound of the formula (I) can be produced using an optically active starting material (IV)′ by the method described in WO03/082333 as shown in the following scheme.
  • Figure US20100120841A1-20100513-C00024
  • wherein each symbol is as defined in the above-mentioned formula (I).
  • Where necessary, the obtained compound of the formula (I) is converted to a pharmaceutically acceptable salt. Formation of salt is known per se, and is performed at room temperature by a well-known method. Not only salts with inorganic acid but also salts with organic acid are considered and, when the compound has a carboxyl group, salts with inorganic base and organic base are also considered. Acid addition salts such as hydrochloride, oxalate, fumarate, maleate and the like, sodium salt, potassium salt, calcium salt, magnesium salt and the like are examples of such salts.
  • The compound of the present invention can be administered orally and parenterally. The dosage form includes tablet, capsule, granule, powder, injection, ointment, suppository and the like. These can be formulated by combining the compound of the present invention with various pharmaceutically acceptable additives such as excipient, bulking agent, lubricant, binder, disintegrant, coating agent, film-forming agent, base, solvent and the like, using conventional techniques.
  • While the dose can be appropriately selected according to symptom, age, dosage form and the like, it is generally 0.1 to 5000 mg, preferably 1 to 1000 mg per day in the case of an oral preparation, which can be administered in one to several portions.
    • EXAMPLES
  • While the results of Examples, Preparation Examples and Pharmacological tests are shown in the following, these Examples are provided for better understanding of the present invention and do not limit the scope of the present invention.
    • Example 1 1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • α-Tetralone (1.0 g) was dissolved in ethanol (20 ml), sodium borohydride (0.26 g) was added, and the mixture was stirred at room temperature for 30 min. 1N Hydrochloric acid (10 ml) was added to cease the reaction. Ethanol was evaporated, and the aqueous solution was extracted with chloroform. The extract was dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was dissolved in chloroform (10 ml), thionyl chloride (1.0 ml) was added, and the mixture was stirred with heating under reflux for 30 min. Chloroform and thionyl chloride were evaporated under reduced pressure, and the residue was dissolved in dimethylformamide (10 ml). Potassium carbonate (2.5 g), 4-(2-keto-1-benzimidazolinyl)piperidine (0.50 g) and sodium iodide (0.69 g) were added, and the mixture was stirred at 150° C. for 2 hr. After cooling to room temperature, water was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was evaporated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (481 mg) as a yellow solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.74 (m, 3H), 1.92-2.05 (m, 3H), 2.27-2.32 (m, 2H), 2.60 (m, 1H), 2.73 (m, 4H), 3.01 (m, 1H), 3.92 (m, 1H), 4.36 (m, 1H), 7.06-7.26 (m, 6H), 7.33 (d, J=7.8 Hz, 1H), 7.80 (d, J=7.5 Hz, 1H), 9.21 (brs, 1H)
  • FAB-MS (M+H)+:348
    • Example 2 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • 1-[1-(1,2,3,4-Tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (476 mg) was dissolved in tetrahydrofuran (5 ml), 60% sodium hydride (66 mg) was added, and the suspension was stirred at 50° C. for 30 min. After cooling to room temperature, ethyl bromoacetate (0.167 ml) was added, and the mixture was stirred for 1 hr. 40% Methylamine-methanol solution (5 ml) was added, the mixture was stirred at room temperature for 1 hr, and the reaction mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (567 mg) as a pale-yellow powder.
  • 1H-NMR (CDCl3) δTMS:1.67-1.74 (m, 3H), 1.93-2.04 (m, 3H), 2.27-2.32 (m, 2H), 2.60 (m, 1H), 2.71-2.86 (m, 7H), 3.02 (m, 1H), 3.92 (m, 1H), 4.35 (m, 1H), 4.51 (s, 2H), 6.18 (brs, 1H), 7.06-7.26 (m, 6H), 7.35 (d, J=7.5 Hz, 1H), 7.78 (d, J=7.6 Hz, 1H)
  • FAB-MS (M+H)+:419
    • Example 3 (R)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) (S)-(+)-1,2,3,4-Tetrahydro-1-naphthol (1.0 g) and diphenylphosphoryl azide (2.23 g) were dissolved in toluene (10 ml), diazabicycloundecene (1.23 g) was added, and the mixture was stirred at room temperature for 6 hr. The reaction mixture was poured into water, the mixture was extracted with toluene, and the combined organic layer was washed with 1N hydrochloric acid and water, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (R)-1-azido-1,2,3,4-tetrahydronaphthalene (1.20 g) as a colorless oil.
  • 1H-NMR (CDCl3) δTMS1.81-1.84 (m, 1H), 1.93-2.04 (m, 3H), 2.77-2.85 (m, 2H), 4.57 (m, 1H), 7.14-7.29 (m, 4H)
  • (2) (R)-1-Azido-1,2,3,4-tetrahydronaphthalene (1.20 g) was dissolved in a mixed solvent (11 ml) of tetrahydrofuran/water (10:1), triphenylphosphine (2.35 g) was added, and the mixture was stirred with heating under reflux for 2 hr. After cooling to room temperature, the solvent was evaporated, 1N hydrochloric acid was added to the residue, and unnecessary substances were removed by extraction with ethyl acetate. The aqueous phase was alkalified with potassium carbonate, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by amine-coated silica gel to give (R)-1,2,3,4-tetrahydronaphthalen-1-ylamine (759 mg) as a colorless oil.
  • 1H-NMR (CDCl3) δTMS: 1.67-1.81 (m, 2H), 1.92-2.05 (m, 2H), 2.34-2.82 (m, 2H), 3.98 (t, J=5.7 Hz, 1H), 7.07-7.19 (m, 3H), 7.41 (d, J=8.7 Hz, 1H)
  • (3) (R)-1,2,3,4-Tetrahydronaphthalen-1-ylamine (759 mg) was dissolved in ethanol (7.3 ml), and potassium carbonate (70 mg) was added. 1-Ethyl-1-methyl-4-oxopiperidinium iodide (1.59 g) dissolved in water (4.4 ml) was added, and the mixture was stirred with heating under reflux for 1 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (R)-1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-one (910 mg) as a pale-yellow oily substance.
  • 1H-NMR (CDCl3) δTMS:1.59-1.69 (m, 2H), 1.96-2.01 (m, 2H), 2.43-2.49 (m, 4H), 2.75-2.82 (m, 4H), 2.86-2.92 (m, 2H), 4.00-4.05 (m, 1H), 7.07-7.22 (m, 3H), 7.77 (d, J=6.9 Hz, 1H)
  • (4) (R)-1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-one (910 mg) was dissolved in tetrahydrofuran (21 ml), and 1,2-phenylenediamine (859 mg) was added. The solution was ice-cooled, sodium triacetoxyborohydride (2.31 g) and acetic acid (0.92 ml) were added, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into water, and the mixture was alkalified with potassium carbonate, and extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (R)-N-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (970 mg) as a pale-yellow solid.
  • 1H-NMR (CDCl3) δTMS:1.40 (m, 1H), 1.55-1.75 (m, 3H), 1.96-2.01 (m, 3H), 2.10 (m, 1H), 2.24 (m, 1H), 2.61-2.83 (m, 5H), 3.20-3.35 (m, 3H), 3.83-3.88 (m, 1H), 6.64-6.80 (m, 4H), 7.07-7.16 (m, 3H), 7.71 (d, J=6.9 Hz, 1H)
  • (5) (R)-N-[1-(1,2,3,4-Tetrahydronaphthalen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (570 mg) was dissolved in tetrahydrofuran (3 ml), 1,1′-carbonyldiimidazole (344 mg) was added, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (543 mg) as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.74 (m, 3H), 1.92-2.05 (m, 3H), 2.27-2.32 (m, 2H), 2.60 (m, 1H), 2.73 (m, 4H), 3.01 (m, 1H), 3.92 (m, 1H), 4.36 (m, 1H), 7.06-7.26 (m, 6H), 7.33 (d, J=7.8 Hz, 1H), 7.80 (d, J=7.5 Hz, 1H), 9.21 (brs, 1H)
  • FAB-MS (M+H)+:348
  • The following compounds can be synthesized according to the above-mentioned Examples.
    • Example 4 (R)-2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using (R)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.65-1.75 (m, 3H), 1.93-2.04 (m, 3H), 2.28-2.33 (m, 2H), 2.60 (m, 1H), 2.70-2.86 (m, 7H), 3.02 (m, 1H), 3.92 (m, 1H), 4.35 (m, 1H), 4.51 (s, 2H), 6.15 (brs, 1H), 7.06-7.26 (m, 6H), 7.35 (d, J=7.5 Hz, 1H), 7.78 (d, J=7.6 Hz, 1H)
  • FAB-MS (M+H)+:419
  • [α]D 24=+17.2°
    • Example 5 (S)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 3 and using (R)-(−)-1,2,3,4-tetrahydro-1-naphthol, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.64-1.73 (m, 3H), 1.92-2.05 (m, 3H), 2.29-2.32 (m, 2H), 2.61 (m, 1H), 2.73 (m, 4H), 3.01 (m, 1H), 3.92 (m, 1H), 4.36 (m, 1H), 7.06-7.26 (m, 6H), 7.33 (d, J=7.2 Hz, 1H), 7.80 (d, J=7.5 Hz, 1H), 9.45 (brs, 1H)
  • FAB-MS (M+H)+:348
    • Example 6 (S)-2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using (S)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.66-1.72 (m, 3H), 1.89-2.03 (m, 3H), 2.28-2.33 (m, 2H), 2.60 (m, 1H), 2.71-2.86 (m, 7H), 3.02 (m, 1H), 3.92 (m, 1H), 4.35 (m, 1H), 4.51 (s, 2H), 6.16 (brs, 1H), 7.06-7.22 (m, 6H), 7.35 (d, J=7.5 Hz, 1H), 7.79 (d, J=7.6 Hz, 1H)
  • FAB-MS (M+H)+:419
  • [α]D 25=+16.8°
    • Example 7 1-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 5-methyl-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.73 (m, 3H), 1.92-2.09 (m, 3H), 2.23 (s, 3H), 2.27-2.32 (m, 2H), 2.57-2.72 (m, 4H), 2.87 (m, 1H), 3.01 (m, 1H), 3.92 (m, 1H), 4.36 (m, 1H), 7.03-7.17 (m, 5H), 7.33 (d, J=8.9 Hz, 1H), 7.72 (d, J=7.7 Hz, 1H), 9.36 (brs, 1H)
  • FAB-MS (M+H)+:362
    • Example 8 2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.74 (m, 3H), 1.89-2.09 (m, 3H), 2.23 (s, 3H), 2.28 (m, 2H), 2.56-2.72 (m, 4H), 2.79 (d, J=4.5 Hz, 3H), 2.85 (m, 1H), 3.02 (m, 1H), 3.90 (m, 1H), 4.35 (m, 1H), 4.51 (s, 2H), 6.16 (brs, 1H), 7.03-7.17 (m, 5H), 7.36 (d, J=7.5 Hz, 1H), 7.70 (d, J=7.86 Hz, 1H)
  • FAB-MS (M+H)+:433
    • Example 9 (R)-1-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) A solution of 5-methyl-1,2,3,4-tetrahydronaphthalen-1-one (3.2 g), (R)-t-butylsulfinamide (2.4 g) and titanium tetraisopropoxide (9.0 g) in tetrahydrofuran (50 ml) was stirred at 75° C. for 96 hr. The reaction mixture was cooled to −50° C., and sodium borohydride (3.0 g) was added by small portions. The mixture was stirred for 7 hr while allowing to warm to room temperature. The reaction mixture was poured into ice water, the mixture was extracted with ethyl acetate, and the extract was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (RS)-2-methyl-N-((S)-5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propane-2-sulfinamide (2.3 g) as a pale-brown solid.
  • 1H-NMR (CDCl3) δTMS:1.21 (s, 9H), 1.79-1.85 (m, 2H), 1.90-2.02 (m, 2H), 2.23 (s, 3H), 2.50-2.60 (m, 1H), 2.70-2.80 (m, 1H), 3.20 (s, 1H), 4.58 (m, 1H), 7.08-7.15 (m, 2H), 7.29-7.31 (m, 1H)
  • (2) (RS)-2-Methyl-N-((S)-5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)propane-2-sulfinamide (277 mg) was dissolved in 5-10% hydrogen chloride-methanol (25 ml) under ice-cooling, and the mixture was stirred for 2 hr under ice-cooling. To the reaction mixture was added 1N aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by aminosilica gel column chromatography (hexane/ethyl acetate) to give (R)-1-amino-5-methyl-1,2,3,4-tetrahydronaphthalene (130 mg) as a brown oily substance.
  • 1H-NMR (CDCl3) δTMS:1.67-1.73 (m, 1H), 1.78-1.85 (m, 1H), 1.92-2.01 (m, 2H), 2.52-2.71 (m, 2H), 3.97-4.00 (m, 1H), 7.03 (d, J=7.3 Hz, 1H), 7.13 (t, J=7.3 Hz, 1H), 7.26 (m, 1H)
  • (3) (R)-1-Amino-5-methyl-1,2,3,4-tetrahydronaphthalene (1.71 g) was dissolved in ethanol (20 ml), and potassium carbonate (1.47 g) was added. 1-Ethyl-1-methyl-4-oxopiperidinium iodide (3.14 g) dissolved in water (5 ml) was added, and the mixture was stirred with heating under reflux for 5 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (R)-1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-one (1.84 g) as a pale-yellow oily substance.
  • 1H-NMR (CDCl3) δTMS:1.50-1.70 (m, 2H), 1.96-1.99 (m, 1H), 2.04-2.09 (m, 1H), 2.22 (s, 1H), 2.43-2.58 (m, 5H), 2.64-2.73 (m, 1H), 2.73-2.2.79 (m, 2H), 2.86-2.92 (m, 2H), 4.01-4.13 (m, 1H), 7.04 (d, J=7.3 Hz, 1H), 7.11 (t, J=7.6 Hz, 1H), 7.68 (d, J=7.6 Hz, 1H)
  • (4) (R)-1-(5-Methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-one (1.84 g) was dissolved in dichloroethane (55 ml), and 1,2-phenylenediamine (1.23 g) was added. To the solution were added sodium triacetoxyborohydride (3.61 g) and acetic acid (0.97 ml). The mixture was stirred at room temperature for 24 hr, alkalified with saturated sodium hydrogen carbonate, and extracted with chloroform. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give (R)-N-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.83 g) as a pale-brown solid.
  • 1H-NMR (CDCl3) δTMS:1.40 (m, 1H), 1.55-1.75 (m, 3H), 1.96-2.01 (m, 2H), 2.04-2.15 (m, 2H), 2.22 (s, 3H), 2.24 (m, 1H), 2.50-2.75 (m, 4H), 2.80-2.90 (m, 1H), 3.20-3.35 (m, 3H), 3.83-3.88 (m, 1H), 6.65-6.80 (m, 4H), 7.01 (d, J=7.2 Hz, 1H), 7.08 (t, J=7.6 Hz, 1H), 7.62 (d, J=7.6 Hz, 1H)
  • (5) (R)-N-[1-(5-Methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.83 g) was dissolved in tetrahydrofuran (100 ml), 1,1′-carbonyldiimidazole (973 mg) was added, and the mixture was stirred at room temperature for 10 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) and crystallized with hexane/ethyl acetate to give the title compound (1.2 g) as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.74 (m, 3H), 1.89-2.15 (m, 3H), 2.22 (s, 3H), 2.27-2.36 (m, 2H), 2.50-2.71 (m, 4H), 2.88 (m, 1H), 3.02 (m, 1H), 3.90 (m, 1H), 4.36 (m, 1H), 7.02-7.16 (m, 5H), 7.34 (d, J=7.6 Hz, 1H), 7.71 (d, J=7.6 Hz, 1H), 9.57 (brs, 1H)
  • FAB-MS (M+H)+:362
  • [α]D 29.7=+38.4 (c=0.5, chloroform)
    • Example 10 (R)-2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • (R)-1-[1-(5-Methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one (995 mg) was dissolved in DMF (10 ml). Sodium hydride (132 mg, 60%) was added, and the suspension was stirred at room temperature for 40 min. Ethyl bromoacetate (458 μl) was added, and the mixture was stirred for 4 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous ammonium chloride solution, dried over sodium sulfate, and concentrated. To the residue was added 40% methylamine-methanol solution (30 ml), the mixture was stirred at room temperature for 2.5 hr, and the reaction mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol), and crystallized with ethyl acetate to give the title compound (1.0 g) as pale-yellow crystals.
  • 1H-NMR (CDCl3) δTMS:1.63-1.74 (m, 3H), 1.89-2.09 (m, 3H), 2.23 (s, 3H), 2.28 (m, 2H), 2.56-2.72 (m, 4H), 2.79 (d, J=4.5 Hz, 3H), 2.85 (m, 1H), 3.02 (m, 1H), 3.90 (m, 1H), 4.35 (m, 1H), 4.51 (s, 2H), 6.16 (brs, 1H), 7.03-7.17 (m, 5H), 7.36 (d, J=7.5 Hz, 1H), 7.70 (d, J=7.86 Hz, 1H)
  • FAB-MS (M+H)+:433
  • [α]D 29.1=+26.8 (c=0.5, chloroform)
    • Example 11 1-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 5-chloro-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.62-1.76 (m, 3H), 1.92-2.10 (m, 3H), 2.28-2.32 (m, 2H), 2.58-2.67 (m, 3H), 2.87-3.04 (m, 3H), 3.88 (m; 1H), 4.35 (m, 1H), 7.06-7.25 (m, 5H), 7.31 (d, J=7.5 Hz, 1H), 7.78 (d, J=7.5 Hz, 1H), 9.40 (brs, 1H)
  • FAB-MS (M+H)+:382
    • Example 12 2-{3-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.62-1.76 (m, 3H), 1.89-2.09 (m, 3H), 2.29 (m, 2H), 2.58-2.68 (m, 3H), 2.79 (d, J=4.8 Hz, 3H), 2.89 (m, 2H), 3.01 (m, 1H), 3.90 (m, 1H), 4.32 (m, 1H), 4.51 (s, 2H), 6.17 (brs, 1H), 7.06-7.19 (m, 5H), 7.32 (d, J=7.5 Hz, 1H), 7.76 (d, J=7.68 Hz, 1H)
  • FAB-MS (M+H)+:453
    • Example 13 1-[1-(5,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 5,7-dimethyl-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.62-1.72 (m, 3H), 1.93-2.13 (m, 3H), 2.19 (s, 3H), 2.27-2.34 (m, 5H), 2.54-2.99 (m, 6H), 3.86 (m, 1H), 4.35 (m, 1H), 6.87 (s, 1H), 7.04-7.14 (m, 3H), 7.34 (d, J=6.9 Hz, 1H), 7.51 (s, 1H), 9.62 (brs, 1H)
  • FAB-MS (M+H)+:376
    • Example 14 2-{3-[1-(5,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(5,7-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.65-1.71 (m, 3H), 1.92-2.07 (m, 3H), 2.19 (s, 3H), 2.25-2.33 (m, 5H), 2.61-2.84 (m, 8H), 3.00 (m, 1H), 3.86 (m, 1H), 4.33 (m, 1H), 4.51 (s, 2H), 6.21 (brs, 1H), 6.88 (s, 1H), 7.06-7.17 (m, 3H), 7.35 (d, J=7.5 Hz, 1H), 7.49 (s, 1H)
  • FAB-MS (M+H)+:447
    • Example 15 1-(1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 1-indanone, the title compound was obtained as a brown solid.
  • 1H-NMR (CDCl3) δTMS:1.78-1.86 (m, 2H), 2.09-2.16 (m, 2H), 2.39 (m, 2H), 2.56 (m, 2H), 2.79-3.09 (m, 4H), 4.35 (m, 1H), 4.44 (m, 1H), 7.04-7.12 (m, 3H), 7.21-7.26 (m, 3H), 7.35 (m, 1H), 7.43 (m, 1H), 9.64 (brs, 1H)
  • FAB-MS (M+H)+:334
    • Example 16 2-{3-(1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-(1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a brown solid.
  • 1H-NMR (CDCl3) δTMS:1.76-1.86 (m, 2H), 2.08-2.16 (m, 2H), 2.39 (m, 2H), 2.55 (m, 2H), 2.80 (d, J=4.9 Hz, 3H), 2.82-3.10 (m, 4H), 4.35 (m, 1H), 4.44 (m, 1H), 4.50 (s, 2H), 6.17 (brs, 1H), 7.05-7.14 (m, 3H), 7.23-7.26 (m, 3H), 7.36-7.43 (m, 2H)
  • FAB-MS (M+H)+:406
    • Example 17 1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one hydrochloride
  • In the same manner as in Example 1 and using 4-fluoro-1-indanone, 1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one was synthesized, which was then converted to hydrochloride with 4N hydrochloric acid-ethyl acetate solution to give the title compound as a brown solid.
  • 1H-NMR (DMSO-d6) δTMS:1.83 (m, 2H), 2.50 (m, 2H), 2.60 (m, 1H) 2.80 (m, 1H), 2.99-3.29 (m, 5H), 3.51 (m, 1H), 4.60 (m, 1H), 5.10 (m, 1H), 6.98 (m, 3H), 7.26 (t, J=9 Hz, 1H), 7.43 (m, 1H), 7.71 (m, 1H), 7.86 (m, J=7.5 Hz, 1H), 10.9 (brs, 1H), 11.6 (brs, 1H)
  • FAB-MS (M+H)+:352
    • Example 18 2-{3-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide hydrochloride
  • In the same manner as in Example 2 and using 1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2-{3-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide was synthesized, which was then converted to hydrochloride with 4N hydrochloric acid-ethyl acetate solution to give the title compound as a pale-yellow solid.
  • 1H-NMR (DMSO-d6) δTMS:1.87 (m, 2H), 2.44 (m, 3H), 2.60 (m, 3H), 2.83 (m, 1H), 3.01-3.41 (m, 5H), 3.53 (m, 1H), 4.43 (s, 2H), 4.67 (m, 1H), 5.10 (m, 1H), 7.05 (m, 3H), 7.27 (t, J=9 Hz, 1H), 7.42 (m, 1H), 7.76 (m, 1H), 7.82 (m, J=7.5 Hz, 1H), 8.11 (brs, 1H), 11.4 (brs, 1H)
  • FAB-MS (M+H)+:423
    • Example 19 1-(4-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 4-methyl-1-indanone, the title compound was obtained as a brown solid.
  • 1H-NMR (CDCl3) δTMS:1.74-1.85 (m, 2H), 2.11-2.16 (m, 2H), 2.27 (s, 3H), 2.39 (m, 2H), 2.54 (m, 2H), 2.74-2.85 (m, 3H), 3.05 (m, 1H), 4.34 (m, 1H), 4.45 (m, 1H), 7.04-7.18 (m, 5H), 7.26-7.34 (m, 2H), 9.54 (brs, 1H)
  • FAB-MS (M+H)+:348
    • Example 20 2-{3-(4-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide hydrochloride
  • In the same manner as in Example 2 and using 1-(4-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2-{3-(4-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide was synthesized, which was then converted to hydrochloride with 4N hydrochloric acid-ethyl acetate solution to give the title compound as a brown solid.
  • 1H-NMR (DMSO-d6) δTMS:1.86 (m, 2H), 2.26 (s, 3H), 2.39 (m, 1H), 2.60 (m, 4H), 2.87 (m, 2H), 3.00-3.26 (m, 5H), 3.49 (m, 1H), 4.43 (s, 2H), 4.66 (m, 1H), 5.04 (m, 1H), 7.04 (m, 3H), 7.24 (m, 2H), 7.79 (m, 2H), 8.12 (m, 1H), 11.3 (brs, 1H)
  • FAB-MS (M+H)+:419
    • Example 21 1-(6-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 6-methyl-1-indanone, the title compound was obtained as a brown solid.
  • 1H-NMR (CDCl3) δTMS:1.78-1.86 (m, 2H), 2.08-2.15 (m, 2H), 2.38 (s, 3H), 2.41 (m, 2H), 2.54 (m, 2H), 2.79-2.89 (m, 3H), 3.05 (m, 1H), 4.33-4.42 (m, 2H), 7.03-7.12 (m, 5H), 7.23 (m, 1H), 7.34 (m, 1H), 9.37 (brs, 1H)
  • FAB-MS (M+H)+:348
    • Example 22 2-{3-(6-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide hydrochloride
  • In the same manner as in Example 2 and using 1-(6-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2-{3-(6-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide was synthesized, which was then converted to hydrochloride with 4N hydrochloric acid-ethyl acetate solution to give the title compound as a brown solid.
  • 1H-NMR (DMSO-d6) δTMS:1.86 (m, 2H), 2.35 (s, 3H), 2.39 (m, 1H), 2.51 (m, 4H), 2.85 (m, 2H), 3.03-3.26 (m, 5H), 3.49 (m, 1H), 4.43 (s, 2H), 4.66 (m, 1H), 4.97 (m, 1H), 7.04 (m, 3H), 7.24 (m, 2H), 7.79 (m, 2H), 8.13 (m, 1H), 11.3 (brs, 1H)
  • FAB-MS (M+H)+:419
    • Example 23 1-(7-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 7-methyl-1-indanone, the title compound was obtained as a brown solid.
  • 1H-NMR (CDCl3) δTMS:1.67 (m, 1H), 1.90 (m, 2H), 2.23 (m, 3H), 2.42 (m, 2H), 2.52 (s, 3H), 2.69 (m, 1H), 2.90 (m, 2H), 3.04 (m, 1H), 4.35 (m, 1H), 4.46 (m, 1H), 7.00-7.22 (m, 7H), 9.33 (brs, 1H)
  • FAB-MS (M+H)+:348
    • Example 24 2-{3-(7-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide hydrochloride
  • In the same manner as in Example 2 and using 1-(7-methyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2-{3-(7-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide was synthesized, which was then converted to hydrochloride with 4N hydrochloric acid-ethyl acetate solution to give the title compound as a brown solid.
  • 1H-NMR (DMSO-d6) δTMS:1.84 (m, 2H), 2.30 (m, 1H), 2.50 (s, 3H), 2.59 (d, J=4.5 Hz, 3H), 2.68-3.01 (m, 4H), 3.23-3.64 (m, 5H), 4.42 (s, 2H), 4.66 (m, 1H), 4.90 (m, 1H), 7.02 (m, 3H), 7.15 (d, J=7.4 Hz, 1H), 7.24 (d, J=7.4 Hz, 1H), 7.33 (t, J=7.5 Hz, 1H), 7.80 (m, 1H), 8.13 (m, 1H), 10.3 (brs, 1H)
  • FAB-MS (M+H)+:419
    • Example 25 1-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 3,3-dimethyl-1-indanone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.20 (s, 3H), 1.39 (s, 3H), 1.80 (m, 1H), 1.94 (m, 3H), 2.29 (m, 2H), 2.65 (m, 2H), 2.75 (m, 1H), 3.10 (m, 1H), 4.38 (m, 1H), 4.54 (m, 1H), 7.05-7.11 (m, 3H), 7.18 (m, 1H), 7.23 (m, 2H), 7.34 (m, 2H), 9.47 (brs, 1H)
  • FAB-MS (M+H)+:362
    • Example 26 2-{3-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.20 (s, 3H), 1.38 (s, 3H), 1.76-1.96 (m, 4H), 2.27-2.40 (m, 2H), 2.62 (m, 2H), 2.75 (m, 1H), 2.79 (d, J=4.7 Hz, 3H), 3.11 (m, 1H), 4.37 (m, 1H), 4.51 (s, 2H), 4.54 (m, 1H), 6.73 (brs, 1H), 7.06-7.19 (m, 4H), 7.25 (m, 2H), 7.38 (m, 2H)
  • FAB-MS (M+H)+:433
    • Example 27 1-[1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 1-benzosuberone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.40 (m, 1H), 1.72 (m, 3H), 1.91-2.15 (m, 6H), 2.34 (m, 1H), 2.49-2.58 (m, 3H), 3.27 (m, 1H), 3.32 (m, 1H), 3.59 (m, 1H), 4.36 (m, 1H), 7.05-7.14 (m, 7H), 7.24 (m, 1H), 9.46 (brs, 1H)
  • FAB-MS (M+H)+:362
    • Example 28 2-{3-[1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a pale-yellow solid.
  • 1H-NMR (CDCl3) δTMS:1.44 (m, 1H), 1.68 (m, 3H), 1.87-2.17 (m, 6H), 2.34 (m, 1H), 2.51-2.63 (m, 3H), 2.79 (d, J=4.9 Hz, 3H), 3.23 (m, 1H), 3.32 (m, 1H), 3.58 (m, 1H), 4.33 (m, 1H), 4.50 (s, 2H), 6.17 (brs, 1H), 7.04-7.14 (m, 7H), 7.26 (m, 1H)
  • FAB-MS (M+H)+:433
  • The following compounds of Examples 29-45 can be synthesized in the same manner as in Example 1.
    • Example 29 1-[1-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 5-methoxy-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.59-1.74 (m, 3H), 1.88-2.06 (m, 3H), 2.26-2.35 (m, 2H), 2.40-2.71 (m, 3H), 2.77-2.89 (m, 2H), 3.02 (m, 1H), 3.82 (s, 3H), 3.89 (m, 1H), 4.35 (m, 1H), 6.72 (d, J=8.0 Hz, 1H), 7.06-7.13 (m, 3H), 7.20 (t, J=8.0 Hz, 1H), 7.33 (d, J=7.4 Hz, 1H), 7.47 (d, J=7.8 Hz, 1H), 8.88 (brs, 1H)
  • FAB-MS (M+H)+:378
    • Example 30 1-[1-(5-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 31 1-[1-(5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 32 1-[1-(5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 33 1-[1-(8-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 34 1-[1-(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 35 1-[1-(7-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 7-fluoro-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.65-1.77 (m, 3H), 1.92 (m, 1H), 2.01-2.05 (m, 2H), 2.31-2.37 (m, 2H), 2.56-2.72 (m, 4H), 2.89 (m, 1H), 3.01 (m, 1H), 3.87 (m, 1H), 4.38 (m, 1H), 6.84 (dt, J=2.7, 8.3 Hz, 1H), 7.00-7.15 (m, 4H), 7.34 (d, J=7.7 Hz, 1H), 7.55 (dd, J=2.7, 10.7 Hz, 1H), 9.28 (brs, 1H)
  • FAB-MS (M+H)+:366
    • Example 36 1-[1-(6-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 37 1-[1-(7-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 38 1-[1-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 39 1-[1-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 7-methoxy-1-tetralone, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.76 (m, 3H), 1.89-2.05 (m, 3H), 2.29-2.36 (m, 2H), 2.57-2.73 (m, 4H), 2.88 (m, 1H), 3.03 (m, 1H), 3.85 (s, 3H), 3.88 (m, 1H), 4.36 (m, 1H), 6.73 (dd, J=2.8, 8.3 Hz, 1H), 6.99 (d, J=8.3 Hz), 7.06-7.11 (m, 3H), 7.32 (d, J=7.6 Hz, 1H), 7.42 (d, J=2.7 Hz, 1H), 9.02 (brs, 1H) FAB-MS (M+H)+:378
    • Example 40 1-[1-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 41 1-[(1-chroman-4-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as in Example 1 and using 4-chromanol, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.75-1.79 (m, 1H), 1.89-1.92 (m, 1H), 1.97-2.15 (m, 2H), 2.25-2.37 (m, 2H), 2.57 (m, 1H), 2.76-2.85 (m, 2H), 3.03 (m, 1H), 3.99 (m, 1H), 4.11-4.16 (m, 1H), 4.18-4.41 (m, 2H), 6.80 (dd, J=0.9, 8.1 Hz, 1H), 6.94 (dt, J=1.0, 7.4 Hz), 7.06-7.15 (m, 4H), 7.30 (d, J=7.1 Hz, 1H), 7.60 (d, J=7.6 Hz, 1H), 8.87 (brs, 1H)
  • FAB-MS (M+H)+:350
    • Example 42 1-[(1-thiochroman-4-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 43 1-[(1,1-dioxide-3,4-dihydro-2H-thiochromen-4-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 44 1-[1-(5-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 45 1-[1-(5-acetoamino-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The compounds of the following Examples 46-74 can be synthesized using the compounds obtained above and in the same manner as in Example 2.
    • Example 46 2-{3-[1-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.63-1.73 (m, 3H), 1.88-2.05 (m, 3H), 2.23-2.35 (m, 2H), 2.46-2.71 (m, 3H), 2.78-2.88 (m, 5H), 3.02 (m, 1H), 3.89 (d, J=4.0 Hz, 1H), 3.89 (m, 1H), 4.34 (m, 1H), 4.50 (d, J=3.7 Hz, 2H), 6.14 (brs, 1H), 6.72 (m, 1H), 7.04-7.21 (m, 4H), 7.36 (m, 1H), 7.46 (m, 1H)
  • FAB-MS (M+H)+:449
    • Example 47 2-{3-[1-(5-trifluoromethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 48 2-{3-[1-(5-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 49 2-{3-[1-(5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 50 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N,N-dimethylacetamide Example 51 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}acetamide Example 52 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-ethylacetamide Example 53 2-{3-[1-(5-cyano-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 54 2-{3-[1-(5-acetylamino-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 55 2-{3-[1-(8-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 56 2-{3-[1-(6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 57 2-{3-[1-(7-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using (RS)-1-[1-(7-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.64-1.78 (m, 3H), 1.89-2.03 (m, 3H), 2.29-2.36 (m, 2H), 2.57-2.72 (m, 4H), 2.80 (d, J=4.9 Hz, 3H), 2.85-2.91 (m, 1H), 3.02 (m, 1H), 3.87 (m, 1H), 4.36 (m, 1H), 4.51 (s, 2H), 6.13 (brs, 1H), 6.85 (m, 1H), 7.00-7.08 (m, 2H), 7.12-7.21 (m, 2H), 7.36 (d, J=7.4 Hz), 7.54 (dd, J=2.6, 10.6 Hz, 1H)
  • FAB-MS (M+H)+:437
    • Example 58 2-{3-[1-(6-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 59 2-{3-[1-(7-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 60 2-{3-[1-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 61 2-{3- [1-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[1-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 35 1H-NMR (CDCl3) δTMS:1.64-1.76 (m, 3H), 1.92-2.01 (m, 3H), 2.28-2.36 (m, 2H), 2.73 (d, J=7.9 Hz, 3H), 2.78-2.89 (m, 1H), 3.02 (m, 1H), 3.84 (s, 3H), 3.88 (m, 1H), 4.35 (m, 1H), 4.50 (s, 2H), 6.14 (brs, 1H), 6.73 (m, 1H), 6.99-7.16 (m, 4H), 7.34 (m, 1H), 7.40 (m, 1H)
  • FAB-MS (M+H)+:449
    • Example 62 2-{3-[1-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 63 1-[2-(methylamino)ethyl]-3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 64 1-[2-(dimethylamino)ethyl]-3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 65 1-(2-methoxyethyl)-3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Example 66 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-cyclopropylacetamide Example 67 2-{3-[1-(1-chroman-4-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as in Example 2 and using 1-[(1-chroman-4-yl)piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.75-1.78 (m, 1H), 1.89-1.92 (m, 1H), 1.97-2.14 (m, 2H), 2.24-2.37 (m, 2H), 2.55-2.62 (m, 1H), 2.75-2.86 (m, 5H), 3.02-3.05 (m, 1H), 3.99 (m, 1H), 4.13-4.19 (m, 1H), 4.33-4.42 (m, 2H), 4.51 (s, 2H), 6.12 (brs, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.94 (dt, J=0.9, 7.4 Hz, 1H), 7.05-7.18 (m, 4H), 7.34 (m, 1H), 7.59 (d, J=7.7 Hz, 1H)
  • FAB-MS (M+H)+:421
    • Example 68 2-{3-[1-(1-thiochroman-4-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 69 2-{3-[1-(1,1-dioxide-3,4-dihydro-2H-thiochromen-4-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 70 2-{3-[1-(5-ethyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 71 2-{3-[1-(8-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 72 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-6-fluoro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 73 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}acetic acid Example 74 2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-thioxo-benzimidazol-1-yl}-N-methylacetamide Example 75 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1) 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine
  • To a solution of ethyl (1,2,3,4-tetrahydronaphthalen-1-yl)acetate (31.0 g) in ethanol (100 ml) was added sodium hydroxide (4N, 100 ml), and the mixture was stirred at room temperature for 1 hr. The reaction mixture was concentrated to a half volume under reduced pressure, and the residue was washed with ethyl acetate. The aqueous layer was acidified with dilute hydrochloric acid, and extracted with chloroform. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered. The solvent was evaporated under reduced pressure to give (1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid.
  • To (1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid was added polyphosphoric acid (75%, 150 g), and the mixture was stirred at 100° C. for 1.5 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one (12.1 g, 37%) as a white solid.
  • 2a,3,4,5-Tetrahydro-2H-acenaphthylen-1-one (4.85 g) was dissolved in methanol (70 ml). Sodium borohydride (1.07 g) was added to the solution under ice-cooling, and the mixture was stirred at room temperature for 1 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-ol.
  • To a cooled (0° C.) solution of 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-ol and diphenylphosphoryl azide (9.31 g) in toluene (90 ml) was added DBU (diazabicycloundecene) (5.04 mL), and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into water, and the mixture was extracted with toluene. The combined organic layer was washed with water, dried over magnesium sulfate, and concentrated. The crude product was dissolved in a mixed solvent (77 ml) of THF/water (10:1), triphenylphosphine (9.61 g) was added, and the mixture was heated under reflux for 1 hr. After cooling to room temperature, the solvent was evaporated, 1N hydrochloric acid (100 ml) was added to the residue, and unnecessary substances were removed by extraction with ethyl acetate. The aqueous phase was alkalified with potassium carbonate, and extracted with chloroform. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine.
    • (2) 1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-one
  • To a mixture of 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine, potassium carbonate (3.89 g) and ethanol (60 ml) was added 1-ethyl-1-methyl-4-oxopiperidinium iodide (8.36 g) dissolved in water (15 ml), and the mixture was heated under reflux for 2 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-one (1.01 g, 14%) as an oil.
    • (3) 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • To a cooled (0° C.) solution of 1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-one (1.00 g, 3.92 mmol) and 1,2-phenylenediamine (642 mg) in dichloroethane (30 ml) were added sodium triacetoxyborohydride (1.99 g) and acetic acid (0.509 ml), and the mixture was stirred at room temperature for 19 hr. The reaction mixture was poured into water, and the mixture was neutralized with potassium carbonate, and extracted with chloroform. The extract was washed with water and saturated brine, dried over sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give N-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.16 g) as an oil.
  • N-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.15 g) was dissolved in THF (70 ml), 1,1′-carbonyldiimidazole (0.591 g) was added, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous ammonium chloride solution, dried over magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (0.76 g) as a white solid.
  • 1H-NMR (CDCl3) δTMS:9.10 (s, 1H), 7.30-7.00 (m, 7H), 4.40-4.30 (m, 1H), 4.06 (d, J=7.8 Hz, 1H), 3.20-3.00 (m, 3H), 2.97-2.62 (m, 2H), 2.60-2.34 (m, 5H), 2.20-2.00 (m, 2H), 1.90-1.60 (m, 6H), 1.18-1.00 (m, 2H).
  • FAB-MS (M+H)+:374
    • Example 76 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • N-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one (0.30 g) was dissolved in DMF (15 ml). Sodium hydride (35 mg, 60%) was added, and the suspension was stirred at room temperature for 30 min. Ethyl bromoacetate (0.1 ml) was added, and the mixture was stirred for 1 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous ammonium chloride solution, dried over magnesium sulfate, and concentrated to give ethyl {3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl} acetate. 40% Methylamine-methanol solution (20 ml) was added, the mixture was stirred at room temperature for 1 hr, and the reaction mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (333 mg) as a white powder.
  • 1H-NMR (DMSO-d6) δTMS:8.10-8.00 (m, 1H), 7.30-6.90 (m, 7H), 4.39 (s, 2H), 4.25-4.05 (m, 1H), 3.93 (d, J=7.5 Hz, 1H), 3.10-2.75 (m, 4H), 2.60-2.52 (m, 3H), 2.40-1.50 (m, 6H), 1.10-0.90 (m, 2H).
  • FAB-MS (M+H)+:445
    • Example 77 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (stereoisomer of Example 75) (1) 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine (stereoisomer of Example 75(1))
  • To a mixture of 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one (12.2 g, 70.9 mmol), hydroxylamine hydrochloride (7.85 g) and water (90 ml) were slowly added sodium acetate (14.5 g), methanol (120 ml), THF (30 ml) and water (60 ml) with stirring while heating at 75° C., and the mixture was stirred for 2 hr and 40 min. After cooling to room temperature, methanol was evaporated under reduced pressure, and the obtained precipitate was collected by filtration, and washed with water to give 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one oxime (13.5 g).
  • To 2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one oxime (7.00 g) was added a solution (about 65%, 50 ml) of sodium bis(2-methoxyethoxy)aluminum dihydride in toluene, and the mixture was stirred with heating at 80° C. for 2 hr. After cooling to room temperature, the reaction mixture was poured into ice water, and the mixture was extracted with chloroform. After concentration under reduced pressure, the residue was extracted with 1N hydrochloric acid. The aqueous layer was alkalified with potassium carbonate, and extracted with chloroform. The extract was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to give the title compound (5.34 g, 83%).
    • (2) 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (stereoisomer of Example 75)
  • In the same manner as Example 75(2) and (3) and using 1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine (stereoisomer of Example 75(1)), the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:9.17 (bs, 1H), 7.40-6.95 (m, 6H), 4.57-4.37 (m, 2H), 3.21-3.06 (m, 1H), 2.91-1.50 (m, 16H), 1.30-1.15 (m, 1H).
  • FAB-MS (M+H)+:374
    • Example 78 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide (stereoisomer of Example 76)
  • In the same manner as Example 76 and using 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (stereoisomer of Example 75), the title compound was obtained as a white solid.
  • 1H-NMR (DMSO-d6) δTMS:8.10-8.05 (m, 1H), 7.38-6.92 (m, 7H), 4.40 (s, 2H), 4.26-4.08 (m, 1H), 3.18-2.99 (m, 1H), 2.82-2.58 (m, 8H), 2.44-1.95 (m, 6H), 1.80-1.05 (m, 5H).
  • FAB-MS (M+H)+:445
    • Example 79 (1RS,3aSR)-2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as Example 76 and using (1RS,3aSR)-1-[1-{(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one (see WO2005/028466, Example 1), the title compound was obtained as a white solid.
  • The obtained (1RS,3aSR)-2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide was resolved into (+) form and (−) form by optical resolution using HPLC.
  • optical resolution analysis conditions
      • column: CHIRALPAK(R)AD-H
      • size: 0.46 cm I.D.×25 cm
      • mobile phase: hexane/ethanol/diethylamine=70/30/0.1(v/v)
      • flow rate: 1.0 ml/min
      • temperature: 40° C.
      • wavelength: 283 nm
        Isomer 1) 1H-NMR (CDCl3) δTMS:7.60-7.53 (m, 1H), 7.39-7.32 (m, 1H), 7.21-6.95 (m, 5H), 6.13 (bs, 1H), 4.51 (s, 2H), 4.41-4.29 (m, 1H), 3.87-3.80 (m, 1H), 3.08-2.97 (m, 1H), 2.90-2.73 (m, 7H), 2.68-2.20 (m, 4H), 2.11-1.20 (m, 15H), 0.92-0.82 (m, 2H).
  • FAB-MS (M+H)+:459
  • [α]D)=−36.6° (c0.24, MeOH)
  • Isomer 2) 1H-NMR (CDCl3) δTMS:7.60-7.53 (m, 1H), 7.39-7.32 (m, 1H), 7.21-6.95 (m, 5H), 6.12 (bs, 1H), 4.51 (s, 2H), 4.41-4.29 (m, 1H), 3.87-3.80 (m, 1H), 3.08-2.97 (m, 1H), 2.90-2.73 (m, 7H), 2.68-2.20 (m, 4H), 2.11-1.20 (m, 15H), 0.92-0.82 (m, 2H).
  • FAB-MS (M+H)+:459
  • [α]D=+ 37.2° (c0.24, MeOH)
    • Example 80 (1RS,3aRS)-2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as Example 76 and using (1RS,3aRS)-1-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (see WO2005/028466, Example 1), the title compound was obtained as a white solid.
  • The obtained (1RS,3aRS) form was resolved into (+) form and (−) form by optical resolution using HPLC.
  • optical resolution analysis conditions
      • column: CHIRALRAI01) IA
      • size: 0.46 cm I.D.×25 cm
      • mobile phase: hexane/ethanol/diethylamine=60/40/0.1(v/v)
      • flow rate: 1.0 ml/min
      • temperature: 40° C.
      • wavelength: 283 nm
        Isomer 1) 1H-NMR (CDCl3) δTMS:7.67-7.48 (m, 1H), 7.40-7.30 (m, 1H), 7.20-6.95 (m, 5H), 6.12 (bs, 1H), 4.51 (s, 2H), 4.40-4.29 (m, 1H), 4.05-3.95 (m, 1H), 3.08-2.97 (m, 1H), 2.87-2.70 (m, 7H), 2.67-2.51 (m, 2H), 2.42-2.25 (m, 2H), 2.10-1.70 (m, 8H), 1.55-1.20 (m, 5H).
  • FAB-MS (M+H)+:459
  • [α]D=+ 54.6° (c0.14, CDCl3)
  • Isomer 2) 1H-NMR (CDCl3) δTMS:7.67-7.48 (m, 1H), 7.40-7.30 (m, 1H), 7.20-6.95 (m, 5H), 6.13 (bs, 1H), 4.51 (s, 2H), 4.40-4.29 (m, 1H), 4.05-3.95 (m, 1H), 3.08-2.97 (m, 1H), 2.87-2.70 (m, 7H), 2.67-2.51 (m, 2H), 2.42-2.25 (m, 2H), 2.10-1.70 (m, 8H), 1.55-1.20 (m, 5H).
  • FAB-MS (M+H)+:459
  • [α]D=−58.3° (c0.13, MeOH)
    • Example 81 1-[1-(2,3,3a,4,5,6-hexahydrobenzo[de]chromen-6-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1) 3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one
  • To a suspension of lithium aluminum hydride (3.45 g) in THF (400 ml) was added dropwise a solution of ethyl chroman-4-ylacetate (10.0 g) in THF (50 ml) under ice-cooling, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture were added water (3.45 ml), 15% aqueous sodium hydroxide solution (3.45 ml) and water (10 ml), and the mixture was filtered, washed with ethyl acetate, and concentrated under reduced pressure to give chroman-4-ylmethanol (7.58 g).
  • To chroman-4-ylmethanol (15.0 g), methylene chloride (80 ml) and triethylamine (12.9 ml) was added dropwise methanesulfonyl chloride (6.85 ml) under ice-cooling, and the mixture was stirred for 2 hr. The reaction mixture was poured into water, and the mixture was extracted with methylene chloride. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give chroman-4-ylmethyl methanesulfonate.
  • To a solution of chroman-4-ylmethyl methanesulfonate in ethanol (650 ml) was added potassium cyanide (9.23 g), and the mixture was stirred with heating under reflux for 15 hr. After cooling to room temperature, the mixture was concentrated under reduced pressure, water was added to the obtained residue, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give 3-chroman-4-ylpropionitrile.
  • A mixture of 3-chroman-4-ylpropionitrile, ethanol (150 ml) and 50% sodium hydroxide (100 ml) was stirred with heating under reflux for 26 hr. After cooling to room temperature, the mixture was washed with ether, and the aqueous layer was acidified with 4N hydrochloric acid, and extracted with chloroform. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated to give 3-chroman-4-ylpropionic acid (9.96 g).
  • To 3-chroman-4-ylpropionic acid (9.95 g) was added polyphosphoric acid (75%, 150 g), and the mixture was stirred at 100° C. for 1.5 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one (4.03 g, 44%) as a yellow solid.
    • (2) 2,3,3a,4,5,6-hexahydro-2H-benzo[de]chromen-6-ylamine
  • In the same manner as Example 75(1) and using 3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one, the title compound was obtained as a white solid.
    • (3) 1-[1-(2,3,3a,4,5,6-hexahydro-benzo[de]chromen-6-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as Example 75(2) and (3) and using 2,3,3a,4,5,6-hexahydro-2H-benzo[de]chromen-6-ylamine, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:9.47 (s, 1H), 7.35-7.25 (m, 2H), 7.13-7.03 (m, 4H), 6.67 (d, J=8.1 Hz, 1H), 4.43-4.32 (m, 2H), 4.13 (t, J=10.8 Hz, 1H), 3.88 (d, J=6.9 Hz, 1H), 3.05-2.50 (m, 5H), 2.40-2.15 (m, 3H), 2.05-1.60 (m, 7H), 1.18-1.05 (m, 1H).
  • FAB-MS (M+H)+:390
    • Example 84 2-{3-[1-(2,3,3a,4,5,6-hexahydro-benzo[de]chromen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as Example 76 and using 1-[1-(2,3,3a,4,5,6-hexahydro-benzo[de]chromen-6-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • 1H-NMR (CDCl3) δTMS:7.36-7.23 (m, 2H), 7.20-7.00 (m, 4H), 6.67 (d, J=7.8 Hz, 1H), 6.16 (bs, 1H), 4.50 (s, 2H), 4.45-4.23 (m, 2H), 4.22-4.09 (m, 1H), 3.90-3.83 (m, 1H), 3.06-2.50 (m, 8H), 2.40-1.60 (m, 9H), 1.25-1.05 (m, 1H).
  • FAB-MS (M+H)+:461
    • Example 83 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1) 1,2,2a,3,4,5-hexahydroacenaphthylen-5-ylamine
  • In the same manner as Example 75(1) and using ethyl indan-1-ylacetate, 2,2a,3,4-tetrahydro-1H-acenaphthylen-5-one was obtained as a white solid.
  • In the same manner as Example 75(1) and using the obtained 2,2a,3,4-tetrahydro-1H-acenaphthylen-5-one, the title compound was obtained as a white solid.
    • (2) 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as Example 75(2) and (3) and using 1,2,2a,3,4,5-hexahydroacenaphthylen-5-ylamine, the title compound was obtained as a white solid.
    • Isomer 1) 1H-NMR(CDCl3) δTMS:9.48 (bs, 1H), 7.53-7.45 (m, 1H), 7.38-7.00 (m, 6H), 4.40-4.23 (m, 1H), 3.93 (d, J=7.8 Hz, 1H), 3.03-2.07 (m, 12H), 1.97-1.83 (m, 1H), 1.73-1.45 (m, 4H), 1.07-0.98 (m, 1H).
  • FAB-MS (M+H)+:373
    • Isomer 2) 1H-NMR (CDCl3) δTMS:9.29 (bs, 1H), 7.50-7.00 (m, 7H), 4.50-4.30 (m, 1H), 4.17-4.00 (m, 1H), 3.10-2.00 (m, 12H), 1.94-1.20 (m, 7H).
  • FAB-MS (M+H)+:373
    • Example 84 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as Example 76 and using 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as a white solid.
  • Isomer 1) 1H-NMR (CDCl3) δTMS:7.50-7.37 (m, 2H), 7.21-7.03 (m, 5H), 6.12 (bs, 1H), 4.51 (s, 2H), 4.41-4.30 (m, 1H), 4.10-4.00 (m, 1H), 3.10-2.77 (m, 9H), 2.67-2.03 (m, 6H), 1.93-1.25 (m, 6H).
  • FAB-MS (M+H)+:445
    • Isomer 2) 1H-NMR (CDCl3) δTMS:7.57-7.50 (m, 1H), 7.46-7.02 (m, 6H), 6.15 (bs, 1H), 4.50 (s, 2H), 4.40-4.25 (m, 1H), 4.00-3.90 (m, 1H), 3.17-2.10 (m, 15H), 1.95-1.47 (m, 5H), 1.17-0.98 (m, 1H).
  • FAB-MS (M+H)+:445
    • Example 85 1-[2-(cyclopropylmethylamino)ethyl]-3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • 1-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one (1.00 g) was dissolved in DMF (30 ml), 60% sodium hydride (140 mg) was added, and the suspension was stirred for 1 hr. Then, N-(2-bromoethyl)phthalimide (818 mg) was added, and the mixture was stirred at 100° C. for 1 hr. The reaction mixture was cooled to room temperature, and poured into saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 2-{2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2-oxobenzimidazol-1-yl}ethyl}isoindole-1,3-dione.
  • 2-{2-{3-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2-oxobenzimidazol-1-yl}ethyl}isoindole-1,3-dione, ethanol (35 ml) and hydrazine (0.42 ml) were stirred with heating under reflux for 2 hr. After cooling to room temperature, the solvent was evaporated, and the residue was purified by silica gel column chromatography (chloroform/methanol) to give 1-(2-aminoethyl)-3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2-oxobenzimidazol-2-one (420 mg, 38%) as an oil.
  • 1-(2-Aminoethyl)-3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2-oxobenzimidazol-2-one (210 mg) was dissolved in dichloroethane (10 ml), and cyclopropanecarboxyaldehyde (41 μL), sodium triacetoxyborohydride (0.248 g) and acetic acid (0.032 ml) were added. The mixture was stirred at room temperature for 13 hr, the reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (80 mg, 34%) as an oil.
  • 1H-NMR (CDCl3) δTMS:7.42-7.38 (m, 1H), 7.22-6.95 (m, 6H), 4.56-4.37 (m, 2H), 4.09-3.95 (m, 2H), 3.20-3.10 (m, 1H), 3.01 (t, J=6.9 Hz, 2H), 2.90-1.50 (m, 19H), 1.37-1.13 (m, 2H), 1.00-0.83 (m, 1H), 0.50-0.37 (m, 2H), 0.17-0.08 (m, 2H).
  • FAB-MS (M+H)+:471
    • Example 86 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-3-(2-isopropylaminoethyl)-1,3-dihydro-2H-benzimidazol-2-one
  • In the same manner as Example 85 and using acetone instead of cyclopropanecarboxyaldehyde, the title compound was obtained as an oil.
  • 1H-NMR (CDCl3) δTMS:7.41-7.37 (m, 1H), 7.22-6.91 (m, 5H), 4.50-4.37 (m, 2H), 3.99 (t, J=6.9 Hz, 2H), 3.20-1.50 (m, 21H), 1.05 (d, J=6.0 Hz, 6H).
  • FAB-MS (M+H)+:459
    • Example 87 3-{3-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}propyl}thiazolidine-2,4-dione
  • To 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (500 mg), dimethylacetamide (3 ml) and potassium carbonate (370 mg) was added 3-brompropanol (0.242 ml), and the mixture was stirred with heating at 85° C. for 2 hr. The reaction mixture was cooled to room temperature, water was added, and the precipitate was collected by filtration to give 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-3-(3-hydroxypropyl)-1,3-dihydro-2H-benzimidazol-2-one.
  • 1-[1-(1,2,2a,3,4,5-Hexahydroacenaphthylen-5-yl)piperidin-4-yl]-3-(3-hydroxypropyl)-1,3-dihydro-2H-benzimidazol-2-one and 2,4-thiazolidinedione (314 mg) were dissolved in THF (25 ml), 40% solution (1.22 ml) of triphenylphosphine (702 mg) and diethyl azodicarboxylate (DEAD) in toluene was added, and the mixture was stirred at 50° C. for 2 hr. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give the title compound (160 mg).
  • 1H-NMR (CDCl3) δTMS:12.3 (bs, 1H), 9.20 (bs, 1H), 7.63-7.42 (m, 2H), 7.38-7.20 (m, 2H), 7.20-7.03 (m, 2H), 7.00-6.92 (m, 1H), 4.85 (d, J=6.3 Hz, 1H), 4.78-4.58 (m, 1H), 4.00-3.85 (m, 3H), 3.81 (s, 2H), 3.66 (t, J=6.9 Hz, 2H), 3.30-2.70 (m, 8H), 2.68-1.80 (m, 8H), 1.70-1.25 (m, 2H)(trifluoroacetate).
  • FAB-MS (M+H)+:531
    • Example 88 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1) 6-fluoro-2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one
  • To a solution of 2-fluorophenethylalcohol (25.0 g) in triethylamine (37.5 ml) and methylene chloride (250 ml) was added dropwise methanesulfonyl chloride (16.7 ml) under ice-cooling, and the mixture was stirred for 30 min. The reaction mixture was cooled to room temperature, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated to give 2-(2-fluorophenyl)ethyl methanesulfonate.
  • To a suspension of 60% sodium hydride (8.24 g) in DMF (200 ml) was added dropwise dimethyl malonate (24.9 g) under ice-cooling, and the suspension was stirred at 50° C. for 30 min. After cooling to room temperature, a solution of 2-(2-fluorophenyl)ethyl methanesulfonate in DMF (30 ml) was added dropwise, and the mixture was stirred at 150° C. for 1 hr. After cooling to room temperature, the reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure to give dimethyl 2-[2-(2-fluorophenyl)ethyl]malonate.
  • Dimethyl 2-[2-(2-fluorophenyl)ethyl]malonate, sodium hydroxide (22.7 g), ethanol (150 ml) and water (100 ml) were heated under reflux for 1.5 hr. The reaction mixture was concentrated under reduced pressure, and the residue was acidified with hydrochloric acid, and extracted with chloroform. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure to give 4-(2-fluorophenyl)butanoic acid.
  • To 4-(2-fluorophenyl)butanoic acid was added polyphosphoric acid (75%, 100 g), and the mixture was stirred at 150° C. for 1.5 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 5-fluoro-3,4-dihydro-2H-naphthalen-1-one (10.2 g, 33%) as an oil.
  • To a suspension of 60% sodium hydride (4.12 g) in toluene (200 ml) was added dropwise ethyl diethylphosphonoacetate (20.4 ml) under ice-cooling, and the mixture was stirred at room temperature for 45 min. Then, a solution of 5-fluoro-3,4-dihydro-2H-naphthalen-1-one (15.3 g) in toluene (50 ml) was added dropwise, and the mixture was stirred at 80° C. for 2 hr. After cooling to room temperature, the reaction mixture was poured into ice water, and the mixture was extracted with toluene. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl (5-fluoro-3,4-dihydro-2H-naphthalen-1-ylidene)acetate.
  • Ethyl (5-fluoro-3,4-dihydro-2H-naphthalen-1-ylidene)acetate, 10% palladium carbon catalyst (3 g) and ethanol (150 ml) were stirred under a hydrogen atmosphere for 4 hr. The reaction mixture was filtered through celite, and concentrated to give ethyl (5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)acetate.
  • To a solution of ethyl 5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)acetate in ethanol (30 ml) was added sodium hydroxide (4N, 30 ml), and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated to ½ under reduced pressure, and the residue was washed with ethyl acetate. The aqueous layer was acidified with dilute hydrochloric acid, and extracted with chloroform. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered, and the solvent was evaporated under reduced pressure to give (5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid.
  • To the obtained (5-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)acetic acid was added polyphosphoric acid (75%, 100 g), and the mixture was stirred at 120° C. for 1 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give 6-fluoro-2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one (6.70 g, 34%) as an orange solid.
    • (2) 6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine
  • In the same manner as Example 75(1) and using 6-fluoro-2a,3,4,5-tetrahydro-2H-acenaphthylen-1-one, the title compound was obtained as an oil.
    • (3) 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol 2-one
  • In the same manner as Example 75(2) and (3) and using 6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-ylamine, the title compound was obtained as an oil.
  • 1H-NMR (CDCl3) δTMS:9.14 (bs, 1H), 7.35-6.80 (m, 6H), 4.42-4.27 (m, 1H), 4.00 (d, J=7.5 Hz, 1H), 3.18-2.97 (m, 3H), 2.96-2.80 (m, 1H), 2.70-2.30 (m, 6H), 2.20-2.03 (m, 2H), 1.87-1.63 (m, 4H), 1.20-1.00 (m, 1H).
  • FAB-MS (M+H)+:392
    • Example 89 2-{3-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • In the same manner as Example 76 and using 1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one, the title compound was obtained as an oil.
  • 1H-NMR (DMSO-d6) δTMS:8.13-8.05 (m, 1H), 7.30-7.22 (m, 1H), 7.20-7.13 (m, 1H), 7.07-6.83 (m, 4H), 4.40 (s, 2H), 4.25-4.10 (m, 1H), 3.92 (d, J=7.6 Hz, 2H), 3.50-3.30 (m, 2H), 3.20-2.72 (m, 4H), 2.59 (d, J=4.8 Hz, 3H), 2.40-2.00 (m, 6H), 1.80-1.52 (m, 4H), 1.10-0.93 (m, 1H).
  • FAB-MS (M+H)+:463
  • In the same manner as in the above-mentioned Examples 75-89, the compounds of the following Examples 90-102 can be obtained.
    • Example 90 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-ethylacetamide Example 91 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-dimethylacetamide Example 92 2-{3-[1-(8-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 93 2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-ethylacetamide Example 94 2-{3-[1-(7-fluoro-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 95 2-{3-[1-(7-methyl-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 96 2-{6-fluoro-3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 97 1-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-3-(2-isopropylaminoethyl)-1,3-dihydro-2H-benzimidazol-2-one Example 98 1-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-3-(2-cyclopropylaminoethyl)-1,3-dihydro-2H-benzimidazol-2-one Example 99 1-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-3-(2-oxo-2-pyrrolidin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-one Example 100 2-{3-[1-(9-fluoro-2,3,3a,4,5,6-hexahydro-benzo[de]chromen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 101 2-{3-[1-(1,2,3,7,8,9,10,10a-octahydrocyclohepta[de]naphthalen-6-yl)piperidin-3-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 102 2-{3-[1-(2,6,7,8,9,9a-hexahydrobenzo[cd]azulen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide Example 103 (R)-1-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) To 4-fluoro-1-naphthylacetic acid (18 g) were added thionyl chloride (70 ml) and N,N-dimethylformamide (several drops), and the mixture was heated under reflux for 1 hr. The reaction mixture was concentrated under reduced pressure, and dichloromethane (1200 ml) was dissolved in the obtained residue. Aluminum chloride (23.5 g) was added under ice-cooling, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was poured into ice water, and the mixture was extracted with chloroform. The extract was washed with water and saturated brine, dried over sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography to give 5-fluoroacenaphthen-1-one (9.4 g).
  • 1H-NMR (CDCl3) δTMS:3.79 (s, 2H), 7.24 (dd, 1H), 7.35-7.40 (m, 1H), 7.77 (t, 1H), 7.78 (d, 1H), 8.24 (d, 1H)
  • (2) To a cooled (−30° C.) solution of (R)-2-methyl-CBS-oxazaborolidine (3.0 ml, 1M toluene solution) was added borane-THF complex (14 ml, 1M THF solution), and the mixture was stirred for 45 min. A solution of 5-fluoroacenaphthen-1-one (2.5 g) in dichloromethane (30 ml) was added dropwise, and the mixture was cooled to and stirred at −30° C. for 1 hr. Then, methanol (8 ml) and 1N hydrochloric acid were added under ice-cooling, and the mixture was extracted with chloroform. The extract was washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated to give (S)-5-fluoro-1-acenaphthenol (2.55 g).
  • 1H-NMR (CDCl3) δTMS:2.07 (brs, 1H), 3.20 (d, 1H), 3.76 (dd, 1H), 5.70-5.80 (m, 1H), 7.20-7.35 (m, 2H), 7.55-7.65 (m, 2H), 7.90 (dd, 1H)
  • (3) To a solution of (S)-5-fluoro-1-acenaphthenol (2.3 g, 12.2 mmol) and diphenylphosphoryl azide (4.4 g, 16 mmol) in toluene (25 ml) was added DBU (2.44 g), and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into water, and the mixture was extracted with toluene. The combined organic layer was washed with 1N hydrochloric acid, dried over magnesium sulfate, and concentrated. A crude azide form product obtained by purification by silica gel column chromatography was dissolved in a mixed solvent (25 ml) of THF/water (10/1). Triphenylphosphine (2.7 g) was added, and the mixture was stirred at room temperature for 18 hr. The solvent was evaporated, 1N hydrochloric acid (200 ml) was added to the residue, and unnecessary substances were removed by extraction with ethyl acetate. The aqueous phase was alkalified with potassium carbonate, and extracted with chloroform. The extract was dried over sodium sulfate, and concentrated to give a amino form crude product. The crude amino form product (1.35 g) was dissolved in ethanol (15 ml). 1-Ethyl-1-methyl-4-oxopiperidinium iodide (2.35 g) dissolved in potassium carbonate (180 mg) and water (5 ml) was added, and the mixture was heated under reflux for 1 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give (R)-1-(5-fluoroacenaphthen-1-yl)-piperidin-4-one (630 mg).
  • 1H-NMR (CDCl3) δTMS:2.40-2.55 (m, 4H), 2.65-2.75 (m, 2H), 2.85-2.95 (m, 2H), 3.25-3.45 (m, 2H), 5.05-5.15 (m, 1H), 7.05-7.20 (m, 2H), 7.50-7.60 (m, 2H), 7.85 (d, 1H)
  • (4) To a cooled (0° C.) solution of (R)-1-(5-fluoroacenaphthen-1-yl)-piperidin-4-one (630 mg) and 1,2-phenylenediamine (510 mg) in THF (100 ml) were added sodium triacetoxyborohydride (1.35 g) and acetic acid (0.6 ml), and the mixture was stirred at room temperature for 12 hr. The reaction mixture was poured into water, and the mixture was neutralized with potassium carbonate, and extracted with chloroform. The extract was washed with water and saturated brine, dried over sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give (R)-N-[1-(5-fluoro-acenaphthen-1-yl)piperidin-4-yl]-benzene-1,2-diamine (1.08 g). The obtained diamine form (1.08 g) was dissolved in THF (10 ml), carbonyldiimidazole (600 mg) was added, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was poured into water, and the mixture was extracted with chloroform. The extract was washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) and recrystallized from a mixed solvent of ethyl acetate/diisopropylether to give the title compound (1.1 g) as a white solid.
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.35-2.60 (m, 4H), 2.75-2.85 (m, 1H), 2.95-3.10 (m, 1H), 3.38 (d, 2H), 4.27-4.40 (m, 1H), 5.00-5.08 (m, 1H), 7.00-7.40 (m, 5H), 7.25-7.35 (m, 1H), 7.55-7.60 (m, 2H), 7.80-7.90 (m, 1H), 9.85 (brs, 1H)
  • FAB-MS (M+H)+:388
    • Example 104 (R)-2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide.maleate
  • (R)-1-[1-(5-Fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.1 g) was dissolve in THF (20 ml). Sodium hydride (150 mg, 60%) was added, and the suspension was stirred at 40° C. for 20 min. After cooling to room temperature, ethyl bromoacetate (550 mg) was added, and the mixture was stirred at 45° C. for 30 min. Then, methylamine (40% methanol solution, 27 ml) was added at room temperature, and the mixture was stirred for 40 min. After confirmation of disappearance of the ester form, the reaction mixture was poured into water, and the mixture was extracted with chloroform. The extract was washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated to give a crude product (1.36 g) of (R)-2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide. The obtained crude product was treated with 1.1 equivalents of maleic acid to give the title compound (950 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.80-2.00 (m, 2H), 2.59 (s, 3H), 2.50-2.70 (m, 1H), 2.80-3.80 (m, 7H), 4.42 (s, 2H), 4.45-4.60 (m, 1H), 5.50-5.60 (m, 1H), 6.07 (s, 2H), 7.00-7.15 (m, 3H), 7.30-7.48 (m, 3H), 7.75-7.80 (m, 1H), 7.88 (brs, 1H), 7.99 (d, 1H), 8.05-8.15 (m, 1H)
  • FAB-MS (M+H)+:459
  • [α]D 20=+26.4°
    • Example 105 1-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • 5-Fluoroacenaphthen-1-one (1.9 g) was dissolved in methanol (40 ml), sodium borohydride (470 mg) was added, and the mixture was stirred at room temperature for 40 min. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-fluoro-1-acenaphthenol (1.8 g). The obtained alcohol form (1.56 g) was dissolved in chloroform (12 ml). Thionyl chloride (2 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (20 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (1.4 g), potassium carbonate (3.4 g) and sodium iodide (1.3 g) were added, and the mixture was stirred at 145° C. for 40 min. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and recrystallized from ethyl acetate to give the title compound (690 mg).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.35-2.60 (m, 4H), 2.75-2.85 (m, 1H), 2.95-3.10 (m, 1H), 3.38 (d, 2H), 4.27-4.40 (m, 1H), 5.00-5.08 (m, 1H), 7.00-7.40 (m, 5H), 7.25-7.35 (m, 1H), 7.55-7.60 (m, 2H), 7.80-7.90 (m, 1H), 9.85 (brs, 1H)
  • FAB-MS (M+H)+:388
    • Example 106 2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide.3/2 maleate
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (700 mg) was treated with 1.5 equivalents of maleic acid to give the title compound (420 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.80-2.00 (m, 2H), 2.59 (s, 3H), 2.55-2.80 (m, 2H), 3.00-3.60 (m, 5H), 3.70-3.90 (m, 2H), 4.42 (s, 2H), 4.50-4.65 (m, 1H), 5.60-5.68 (m, 1H), 6.12 (s, 3H), 7.00-7.15 (m, 3H), 7.30-7.35 (d, 1H), 7.37-7.48 (m, 1H), 7.78-7.85 (m, 1H), 7.83 (d, 1H), 7.90 (d, 1H), 8.08-8.15 (m, 1H)
  • FAB-MS (M+H)+:459
    • Example 107 1-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) To a mixture (11 g) of 2-chloro-1-naphthylacetic acid and 7-chloro-1-naphthylacetic acid were added thionyl chloride (50 ml) and N,N-dimethylformamide (several drops), and the mixture was heated under reflux for 1 hr. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in dichloromethane (500 ml). Aluminum chloride (13 g) was added under ice-cooling, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into ice water, and the mixture was extracted with chloroform. The extract was washed with water and saturated brine, dried over sodium sulfate, and concentrated. The residue was isolated and purified by silica gel column chromatography to give 3-chloroacenaphthen-1-one (600 mg) and 8-chloroacenaphthen-1-one (3.0 g).
  • 3-chloroacenaphthen-1-one
  • 1H-NMR (CDCl3) δTMS:3.82 (s, 2H), 7.26 (d, 1H), 7.54 (t, 1H), 7.70 (d, 1H), 7.98 (d, 1H), 8.07 (d, 1H)
  • 8-chloroacenaphthen-1-one
  • 1H-NMR (CDCl3) δTMS:3.84 (s, 2H), 7.25 (d, 1H), 7.49 (d, 1H), 7.55-7.65 (m, 2H), 7.80 (d, 1H), 8.08 (d, 1H)
  • (2) 3-Chloroacenaphthen-1-one (1.0 g) was dissolved in methanol (25 ml), sodium borohydride (220 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 3-chloro-1-acenaphthenol (1.0 g). The alcohol form (1.0 g) was dissolved in chloroform (15 ml). Thionyl chloride (2 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (12 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (900 mg), potassium carbonate (2.2 g) and sodium iodide (800 mg) were added, and the mixture was stirred at 145° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and recrystallized from ethyl acetate to give the title compound (1.0 g).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.35-2.65 (m, 4H), 2.70-2.80 (m, 1H), 3.00-3.10 (m, 1H), 3.35-3.45 (m, 2H), 4.30-4.40 (m, 1H), 4.90-5.00 (m, 1H), 7.00-7.15 (m, 3H), 7.25-7.35 (m, 1H), 7.49 (d, 1H), 7.50-7.60 (m, 3H), 7.70 (d, 1H), 9.60 (brs, 1H)
  • FAB-MS (M+H)+:404
    • Example 108 2-{3-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide.1/2 fumarate
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.3 g) was treated with 1.0 equivalent of fumaric acid to give the title compound (277 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.60-1.80 (m, 2H), 2.25-2.60 (m, 5H), 2.60 (s, 3H), 2.90-3.05 (m, 1H), 3.15-3.55 (m, 3H), 4.25-4.40 (m, 1H), 4.41 (s, 2H), 5.00-5.10 (m, 1H), 6.62 (s, 1H), 7.00-7.15 (m, 2H), 7.30 (d, 1H), 7.48 (d, 1H), 7.55-7.65 (m, 2H), 7.74 (d, 1H), 7.75-7.85 (m, 1H), 8.05-8.15 (m, 1H)
  • FAB-MS (M+H)+:475
    • Example 109 1-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) Acenaphthen-1-one (11 g) was dissolved in N,N-dimethylformamide (80 ml), N-chlorosuccinimide (9.0 g) was added, and the mixture was stirred at room temperature for 2 days. The reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and recrystallized from ethanol to give crude crystals (3.5 g) of 5-chloroacenaphthen-1-one.
    (2) 5-Chloroacenaphthen-1-one (1.9 g) was dissolved in methanol (35 ml), sodium borohydride (430 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-chloro-1-acenaphthenol (1.9 g).
  • 1H-NMR (CDCl3) δTMS:1.80-2.30 (brs, 1H), 3.20 (d, 1H), 3.77 (dd, 1H), 5.70-5.75 (m, 1H), 7.21 (d, 1H), 7.52 (d, 1H), 7.55-7.60 (m, 1H), 7.66 (dd, 1H), 7.99 (d, 1H)
  • (3) The alcohol form (1.9 g) was dissolved in chloroform (20 ml). Thionyl chloride (3 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and N,N-dimethylformamide (20 ml) was dissolved in the obtained residue. 4-(2-Keto-1-benzimidazolinyl)piperidine (1.7 g), potassium carbonate (4.14 g) and sodium iodide (1.5 g) were added, and the mixture was stirred at 140° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (1.1 g).
  • 1H-NMR (DMSO6) δTMS:1.50-1.70 (m, 2H), 2.25-2.60 (m, 5H), 2.90-3.00 (m, 1H), 3.30-3.40 (m, 2H), 4.05-4.20 (m, 1H), 4.95-5.00 (m, 1H), 6.90-7.00 (m, 3H), 7.23 (d, 1H), 7.33 (d, 1H), 7.62 (m, 2H), 7.73 (dd, 1H), 7.86 (d, 1H), 10.82 (brs, 1H)
  • FAB-MS (M+H)+:404
    • Example 110 2-{3-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.3 g) was washed by suspending in acetone to give the title compound (237 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.60-1.75 (m, 2H), 2.25-2.65 (m, 5H), 2.59 (s, 3H), 2.90-3.00 (m, 1H), 3.30-3.40 (m, 2H), 4.10-4.20 (m, 1H), 4.41 (s, 2H), 4.95-5.05 (m, 1H), 7.00-7.10 (m, 3H), 7.25-7.35 (m, 2H), 7.55-7.65 (m, 2H), 7.70-7.80 (dd, 1H), 7.80-7.90 (d, 1H), 8.05-8.15 (brs, 1H)
  • FAB-MS (M+H)+:475
    • Example 111 1-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.hydrochloride
  • (1) 8-Chloroacenaphthen-1-one (2.0 g, 9.87 mmol) was dissolved in methanol (40 ml), sodium borohydride (400 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 8-chloro-1-acenaphthenol (2.0 g).
  • 1H-NMR (CDCl3) δTMS:1.50-1.60 (brs, 1H), 3.30 (d, 1H), 3.79 (dd, 1H), 5.70-5.80 (m, 1H), 7.34 (d, 1H), 7.42 (d, 1H), 7.48 (dd, 1H), 7.63 (d, 1H), 7.69 (d, 1H)
  • (2) The alcohol form (2.0 g) was dissolved in chloroform (18 ml). Thionyl chloride (2 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (20 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (1.7 g), potassium carbonate (4.14 g) and sodium iodide (1.5 g) were added, and the mixture was stirred at 140° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give crude crystals (2.1 g) of (RS)-1-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one. The crude crystals were treated with 4N hydrochloric acid-ethyl acetate solution and recrystallized from acetone to give the title compound (305 mg).
  • 1H-NMR (DMSO6) δTMS: 1.65-1.75 (m, 1H), 1.90-2.00 (m, 1H), 2.60-2.75 (m, 1H), 2.80-3.15 (m, 3H), 3.60-3.75 (m, 1H), 3.80-3.90 (m, 2H), 4.05-4.20 (m, 1H), 3.50-3.65 (m, 1H), 5.55-5.70 (m, 1H), 6.90-7.00 (m, 3H), 7.50-7.60 (m, 1H), 7.60-7.75 (m, 3H), 7.84 (d, 1H), 8.05 (d, 1H), 10.92 (brs, 1H), 11.67 (brs, 1H)
  • FAB-MS (M+H)+:404
    • Example 112 2-{3-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide-oxalate
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.2 g) was treated with 1.1 equivalents of oxalic acid to give the title compound (473 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.55-1.65 (m, 1H), 1.70-1.80 (m, 1H), 2.60 (s, 3H), 2.25-2.70 (m, 5H), 3.05-3.15 (m, 1H), 3.35-3.45 (m, 1H), 3.55-3.65 (m, 1H), 4.20-4.30 (m, 1H), 4.40 (s, 2H), 5.15-5.25 (m, 1H), 7.00-7.10 (m, 3H), 7.26 (d, 1H), 7.43 (d, 1H), 7.50-7.60 (m, 2H), 7.73 (d, 1H), 7.85 (d, 1H), 8.10 (brs, 1H)
  • FAB-MS (M+H)+:475
    • Example 113 1-[1-(5-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H -benzimidazol-2-one
  • (1) Acenaphthen-1-one (25 g) was dissolved in N,N-dimethylformamide (200 ml), N-bromosuccinimide (27 g) was added, and the mixture was stirred at room temperature for 2 days. The precipitated crystals were collected by filtration, and recrystallized from ethanol to give 5-bromoacenaphthen-1-one (16 g).
  • 1H-NMR (CDCl3) δTMS:3.79 (s, 2H), 7.33 (d, 1H), 7.80-7.90 (m, 2H), 8.01 (d, 1H), 8.28 (d, 1H)
  • (2) 5-Bromoacenaphthen-1-one (5.3 g) was dissolved in methanol (80 ml), sodium borohydride (1.0 g) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-bromo-1-acenaphthenol (4.4 g).
  • 1H-NMR (CDCl3) δTMS:1.60-1.80 (brs, 1H), 3.19 (d, 1H), 3.76 (dd, 1H), 5.74 (d, 1H), 7.17 (d, 1H), 7.60 (d, 1H), 7.67 (dd, 1H), 7.72 (d, 1H), 7.94 (d, 1H)
  • (3) The alcohol form (4.4 g) was dissolved in chloroform (40 ml). Thionyl chloride (5 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (40 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (3.2 g), potassium carbonate (7.0 g) and sodium iodide (2.65 g) were added, and the mixture was stirred at 140° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give crude crystals (8.0 g). The crude crystals (300 mg) were washed by suspending in acetone to give the title compound (121 mg).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.35-2.60 (m, 4H), 2.70-2.80 (m, 1H), 3.00-3.10 (m, 1H), 3.35-3.40 (m, 2H), 4.25-4.40 (m, 1H), 4.95-5.05 (m, 1H), 7.00-7.10 (m, 3H), 7.17 (d, 1H), 7.25-7.35 (m, 1H), 7.59 (d, 1H), 7.60-7.70 (m, 2H), 7.89 (d, 1H), 8.78 (brs, 1H)
  • FAB-MS (M+H)+:450
    • Example 114 2-{3-[1-(5-bromoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(5-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.2 g) was washed by suspending in acetone to give the title compound (597 mg).
  • 1H-NMR (DMSO-d6) δTMS:1.50-1.75 (m, 2H), 2.20-2.60 (m, 5H), 2.59 (s, 3H), 2.90-3.00 (m, 1H), 3.30-3.45 (m, 1H), 4.00-4.40 (m, 2H), 4.42 (s, 2H), 4.95-5.05 (m, 1H), 6.85-7.10 (m, 3H), 7.25-7.35 (m, 2H), 7.63 (d, 1H), 7.70-7.85 (m, 3H), 8.19 (m, 1H)
  • FAB-MS (M+H)+:521
    • Example 115 1-[1-(3-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) To a mixture (43 g) of 2-bromo-1-naphthylacetic acid and 7-bromo-1-naphthylacetic acid were added thionyl chloride (100 ml) and N,N-dimethylformamide (several drops), and the mixture was heated under reflux for 1 hr. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in dichloromethane (1000 ml). Aluminum chloride (43 g) was added under ice-cooling, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was poured into ice water, and the mixture was extracted with chloroform. The extract was washed with water and saturated brine, dried over sodium sulfate, and concentrated. The residue was isolated and purified by silica gel column chromatography to give 3-bromoacenaphthen-1-one (1.5 g) and 8-bromoacenaphthen-1-one (6.8 g).
  • 3-bromoacenaphthen-1-one
  • 5 1H-NMR (CDCl3) δTMS:3.77 (s, 2H), 7.66 (d, 1H), 7.70-7.75 (m, 2H), 7.97 (d, 1H), 8.06 (d, 1H)
  • 8-bromoacenaphthen-1-one
  • 1H-NMR (CDCl3) δTMS:3.85 (s, 2H), 7.49 (d, 1H), 7.61 (dd, 1H), 7.74-7.80 (m, 2H), 7.89 (d, 1H)
  • (2) 3-Bromoacenaphthen-1-one (1.5 g, 6.07 mmol) was dissolved in methanol (30 ml), sodium borohydride (280 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 3-bromo-1-acenaphthenol (1.6 g). The alcohol form (1.6 g) was dissolved in chloroform (18 ml). Thionyl chloride (2 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (13 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (1.5 g, 5.26 mmol), potassium carbonate (2.7 g) and sodium iodide (970 mg) were added, and the mixture was stirred at 140° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and recrystallized from acetone to give the title compound (1.8 g).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.40-2.60 (m, 4H), 2.70-2.80 (m, 1H), 3.00-3.10 (m, 1H), 3.35-3.45 (m, 2H), 4.30-4.40 (m, 1H), 4.90-5.00 (m, 1H), 7.00-7.15 (m, 3H), 7.25-7.35 (m, 1H), 7.50-7.60 (m, 4H), 7.60-7.70 (m, 1H), 9.85 (brs, 1H)
  • FAB-MS (M+H)+:450
    • Example 116 2-{3-[1-(3-bromoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(3-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (700 mg) was recrystallized from acetone to give the title compound (125 mg). 1H-NMR (CDCl3) δTMS:1.60-1.75 (m, 2H), 2.25-2.65 (m, 7H), 2.59 (s, 3H), 2.90-3.00 (m, 1H), 3.30-3.40 (m, 1H), 4.15-4.25 (m, 1H), 4.41 (s, 2H), 5.01 (brs, 1H), 6.95-7.10 (m, 3H), 7.31 (d, 1H), 7.55-7.70 (m, 3H), 7.79 (d, 1H), 8.05-8.15 (m, 1H)
  • FAB-MS (M+H)+:521
    • Example 117 1-[1-(8-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) 8-Bromoacenaphthen-1-one (2.4 g) was dissolved in methanol (45 ml), sodium borohydride (450 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product (2.2 g) of 8-bromo-1-acenaphthenol.
    (2) The crude product of the alcohol form (2.2 g) was dissolved in chloroform (18 ml). Thionyl chloride (2.5 ml) was added under ice-cooling, and the mixture was heated under reflux for 1 hr. The solvent was evaporated, and the obtained residue was dissolved in N,N-dimethylformamide (18 ml). 4-(2-Keto-1-benzimidazolinyl)piperidine (2.0 g), potassium carbonate (3.7 g) and sodium iodide (1.35 g) were added, and the mixture was stirred at 140° C. for 1 hr. After allowing to cool, the reaction mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and recrystallized from ethyl acetate to give the title compound (1.1 g).
  • 1H-NMR (CDCl3) δTMS:1.60-1.70 (m, 1H), 1.80-1.90 (m, 1H), 2.25-2.50 (m, 3H), 2.50-2.70 (m, 2H), 3.15-3.30 (m, 2H), 3.45-3.55 (m, 1H), 4.30-4.40 (m, 1H), 4.90-5.00 (m, 1H), 7.00-7.15 (m, 3H), 7.25-7.40 (m, 2H), 7.48 (dd, 1H), 7.50-7.65 (m, 3H), 9.48 (brs, 1H)
  • FAB-MS (M+H)+:450
    • Example 118 2-{3-[1-(8-bromoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(8-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (500 mg) was recrystallized from ethyl acetate to give the title compound (285 mg).
  • 1H-NMR (CDCl3) δTMS:1.60-1.70 (m, 1H), 1.80-1.90 (m, 1H), 2.20-2.30 (m, 1H), 2.30-2.40 (m, 2H), 2.50-2.75 (m, 2H), 2.78 (d, 3H), 3.15-3.30 (m, 2H), 3.45-3.55 (m, 1H), 4.30-4.40 (m, 1H), 4.49 (s, 2H), 4.95-5.00 (m, 1H), 6.15 (brs, 1H), 7.00-7.10 (m, 1H), 7.10-7.20 (m, 2H), 7.30-7.40 (m, 2H), 7.48 (dd, 1H), 7.75-7.65 (m, 3H)
  • FAB-MS (M+H)+:521
    • Example 119 1-[1-(3-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • 1-[1-(3-Bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.25 g) was dissolved in N,N-dimethylformamide (16 ml), zinc cyanide (380 mg) and tetrakistriphenylphosphinepalladium (1.6 g) were added, and the mixture was stirred at 110° C. for 1 hr. After allowing to cool, water and ethyl acetate were poured into the reaction mixture, and the mixture was subjected to celite filtration. The filtrate was extracted with ethyl acetate, and the extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography, and recrystallized from acetone to give the title compound (1.0 g).
  • 1H-NMR (CDCl3) δTMS:1.60-1.80 (m, 2H), 2.40-2.65 (m, 4H), 2.70-2.80 (m, 1H), 3.00-3.10 (m, 1H), 3.55-3.65 (m, 2H), 4.25-4.40 (m, 1H), 5.00-5.10 (m, 1H), 7.00-7.15 (m, 3H), 7.20-7.30 (m, 1H), 7.35-7.50 (m, 1H), 7.57 (d, 1H), 7.60-7.80 (m, 3H), 9.55 (brs, 1H)
  • FAB-MS (M+H)+:395
    • Example 120 2-{3-[1-(3-cyanoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(3-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (800 mg) was recrystallized from a mixed solvent of acetone/ethyl acetate to give the title compound (450 mg).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 3H), 2.40-2.65 (m, 3H), 2.70-2.80 (m, 1H), 2.78 (d, 3H), 3.00-3.20 (m, 1H), 3.55-3.60 (m, 2H), 4.25-4.40 (m, 1H), 4.49 (s, 2H), 5.03-5.06 (m, 1H), 6.18 (brs, 1H), 7.00-7.20 (m, 3H), 7.33 (d, 1H), 7.57 (d, 1H), 7.65-7.80 (m, 4H)
  • FAB-MS (M+H)+:466
    • Example 121 1-[1-(5-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • A crude product obtained in the same manner as Example 119 and using 1-[1-(5-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (2.5 g) was recrystallized from acetone to give the title compound (850 mg).
  • 1H-NMR (DMSO6) δTMS:1.55-1.70 (m, 2H), 2.25-2.60 (m, 5H), 2.90-3.00 (m, 1H), 3.45-3.50 (m, 2H), 4.10-4.20 (m, 1H), 5.00-5.10 (m, 1H), 6.90-7.00 (m, 3H), 7.22 (d, 1H), 7.51 (d, 1H), 7.72 (d, 1H), 7.80-7.90 (m, 2H), 8.11 (d, 1H), 10.83 (brs, 1H)
  • FAB-MS (M+H)+:395
    • Example 122 2-{3-[1-(5-cyanoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide.oxalate
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(5-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (550 mg) was treated with 1.1 equivalents of oxalic acid to give the title compound (481 mg).
  • 1H-NMR (DMSO6) δTMS:1.70-1.85 (m, 2H), 2.45-2.70 (m, 2H), 2.60 (s, 3H), 2.70-2.95 (m, 3H), 3.20-3.30 (m, 1H), 3.60-3.80 (m, 2H), 4.35-4.50 (m, 1H), 4.41 (s, 2H), 5.30-5.40 (m, 1H), 7.00-7.10 (m, 3H), 7.30-7.40 (m, 1H), 7.58 (d, 1H), 7.85-8.00 (m, 3H), 8.05-8.15 (m, 1H), 8.17 (d, 1H)
  • FAB-MS (M+H)+:466
    • Example 123 1-[1-(8-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • A crude product obtained in the same manner as Example 119 and using 1-[1-(8-bromoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.0 g) was recrystallized from a mixed solvent of acetone/ethyl acetate to give the title compound (1.4 g).
  • 1H-NMR (CDCl3) δTMS:1.65-1.75 (m, 1H), 1.85-1.95 (m, 1H), 2.30-2.60 (m, 3H), 2.65-2.80 (m, 2H), 3.25-3.40 (m, 2H), 3.50-3.60 (m, 1H), 4.40-4.55 (m, 1H), 5.10-5.20 (m, 1H), 7.00-7.15 (m, 3H), 7.40-7.50 (m, 2H), 7.60-7.70 (m, 3H), 7.75 (d, 1H), 9.63 (brs, 1H)
  • FAB-MS (M+H)+:395
    • Example 124 2-{3-[1-(8-cyanoacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(8-cyanoacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.3 g) was purified twice by silica gel chromatography to give the title compound (122 mg).
  • 1H-NMR (CDCl3) δTMS:1.70-1.95 (m, 2H), 2.30-2.60 (m, 3H), 2.60-2.80 (m, 2H), 2.78 (d, 2H), 3.25-3.35 (m, 2H), 3.50-3.60 (m, 1H), 4.40-4.45 (m, 1H), 4.50 (s, 2H), 5.10-5.20 (m, 1H), 6.20 (brs, 1H), 7.04 (d, 2H), 7.11 (dd, 1H), 7.17 (dd, 1H), 7.40-7.50 (m, 1H), 7.51 (d, 1H), 7.60-7.70 (m, 3H), 7.68 (d, 1H)
  • FAB-MS (M+H)+:466
    • Example 125 1-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • (1) 5-Bromo-1-acenaphthenol (6.4 g) and tert-butyldimethylsilyl chloride (4.6 g) were dissolved in N,N-dimethylformamide (20 ml), imidazole (4.1 g) was added while stirring the mixture at room temperature, and the mixture was stirred at 40° C. for 30 min. After completion of the reaction, the mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5-bromo-1-(tert-butoxydimethylsilyloxy)acenaphthene (8.3 g).
  • 1H-NMR (CDCl3) δTMS:0.10 (s, 6H), 0.86 (s, 9H), 3.05 (dd, 1H), 3.56 (dd, 1H), 5.60-5.70 (m, 1H), 6.99 (d, 1H), 7.35 (d, 1H), 7.45-7.60 (m, 2H), 7.77 (d, 1H)
  • (2) 5-Bromo-1-(tert-butoxydimethylsilyloxy)acenaphthene (3.0 g) was dissolved in tetrahydrofuran (40 ml), and n-butyllithium-hexane solution (1.6 mol/l, 5.5 ml) was added dropwise under a nitrogen stream while cooling the mixture to −78° C. After stirring at −78° C. for 1 hr, a solution of N,N-dimethylformamide (640 mg) in tetrahydrofuran was added dropwise, and the mixture was further stirred for 15 min. After completion of the reaction, 1N hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure to give a crude product of (RS)-5-formyl-1-(tert-butoxydimethylsilyloxy)acenaphthene. The crude product of the formyl form was dissolved in dichloromethane (60 ml), m-chloroperbenzoic acid (65%, 3.8 g) was added under ice-cooling, and the mixture was stirred at room temperature for 15 hr. After completion of the reaction, the mixture was extracted with chloroform, and the extract was washed with saturated aqueous sodium hydrogen carbonate solution, and dried over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5-hydroxy-1-(tert-butoxydimethylsilyloxy)acenaphthene (2.1 g).
  • 1H-NMR (CDCl3) δTMS:0.10 (s, 6H), 0.86 (s, 9H), 3.09 (dd, 1H), 3.60 (dd, 1H), 5.65-5.70 (m, 1H), 7.10-7.15 (m, 2H), 7.36 (d, 1H), 7.47 (dd, 1H), 7.56 (d, 1H), 8.36 (s, 1H)
  • (3) To a solution of 5-hydroxy-1-(tert-butoxydimethylsilyloxy)acenaphthene (8.5 g) in N,N-dimethylformamide (70 ml) was added potassium carbonate (6.0 g), methyl iodide (5.0 g) was added dropwise thereto while stirring the mixture at room temperature, and the mixture was stirred for 9 hr. After completion of the reaction, the mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give (RS)-5-methoxy-1-(tert-butoxydimethylsilyloxy)acenaphthene (7.7 g).
  • 1H-NMR (CDCl3) δTMS:0.10 (s, 6H), 0.86 (s, 9H), 3.04 (dd, 1H), 3.55 (dd, 1H), 3.86 (s, 3H), 5.65-5.70 (m, 1H), 6.66 (d, 1H), 7.02 (d, 1H), 7.32 (d, 1H), 7.40 (dd, 1H), 7.82 (d, 1H)
  • (4) 5-Methoxy-1-(tert-butoxydimethylsilyloxy)acenaphthene (7.7 g) was dissolved in tetrahydrofuran (100 ml), a solution (120 ml) of tetrabutylammonium fluoride (1.0 mol) in tetrahydrofuran was added dropwise under ice-cooling, and the mixture was stirred at room temperature for 1 hr. After completion of the reaction, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate. The extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5-methoxy-1-acenaphthenol (4.0 g). A crude product obtained in the same manner as Example 103 (3) ff. and using the obtained alcohol form (4.0 g) was recrystallized from acetone to give the title compound (1.6 g).
  • 1H-NMR (CDCl3) δTMS:1.70-1.90 (m, 2H), 2.35-2.65 (m, 4H), 2.75-2.85 (m, 1H), 2.95-3.05 (m, 1H), 3.30-3.40 (m, 2H), 3.98 (s, 3H), 4.25-4.40 (m, 1H), 4.90-5.00 (m, 1H), 6.78 (d, 1H), 7.00-7.15 (m, 3H), 7.15-7.20 (d, 1H), 7.25-7.35 (m, 1H), 7.50-7.60 (m, 2H), 7.94 (d, 1H), 9.97 (brs, 1H)
  • FAB-MS (M+H)+:400
    • Example 126 2-{3-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • A crude product obtained in the same manner as Example 104 and using 1-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (400 mg) was recrystallized from ethyl acetate to give the title compound.
  • 1H-NMR (CDCl3) δTMS:1.70-1.85 (m, 3H), 2.35-2.60 (m, 4H), 2.78 (d, 3H), 3.00-3.05 (m, 1H), 3.30-3.40 (m, 2H), 3.99 (s, 3H), 4.25-4.40 (m, 1H), 4.49 (s, 2H), 4.95-5.00 (m, 1H), 6.14 (brs, 1H), 6.79 (d, 1H), 7.00-7.20 (m, 4H), 7.30-7.40 (m, 1H), 7.45-7.60 (m, 2H), 7.90-8.00 (m, 1H)
  • FAB-MS (M+H)+:471
    • Example 127 1-[1-(5-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The title compound is obtained according to the method of Example 128 and using 1-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 128 2-{3-[1-(5-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • 2-{3-[1-(5-Methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide (780 mg) was dissolved in dichloromethane (50 ml), a solution (8.0 ml) of boron tribromide (1.0 mol) in dichloromethane was added dropwise under a nitrogen stream while cooling to −50° C., and the mixture was gradually warmed over 1 hr. After completion of the reaction, the reaction mixture was poured into an aqueous potassium carbonate solution by small portions, during which unnecessary substances were dissolved in acetone), the mixture was extracted with chloroform, and the extract was dried over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by NH-coating silica gel column chromatography to give a crude product of the title compound.
  • 1H-NMR (DMSO-d6) δTMS:1.55-1.80 (m, 2H), 2.45-2.60 (m, 5H), 2.60 (s, 3H), 2.90-3.00 (m, 1H), 3.15-3.35 (m, 3H), 4.10-4.25 (m, 1H), 4.41 (s, 2H), 4.90-5.00 (m, 1H), 6.82 (d, 1H), 7.00-7.15 (m, 3H), 7.30 (d, 1H), 7.40-7.50 (m, 2H), 7.75-7.85 (m, 1H), 8.08-8.15 (m, 1H), 9.78 (brs, 1H)
  • FAB-MS (M+H)+:457
    • Example 129 1-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The title compound is obtained according to the method of Example 125 and using 3-bromo-1-acenaphthenol.
    • Example 130 2-{3-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound is obtained according to the method of Example 104 and using 1-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 131 1-[1-(3-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The title compound is obtained according to the method of Example 128 and using 1-[1-(3-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 132 2-{3-[1-(3-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound is obtained according to the method of Example 104 and using 1-[1-(3-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 133 1-[1-(8-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • A known compound, 8-hydroxyacenaphthen-1-one (7.0 g) (J. Chem. Soc., 1954, p. 4299), was dissolved in N,N-dimethylformamide (70 ml), potassium carbonate (7.9 g) and methyl iodide (6.8 g) were added, and the mixture was stirred at room temperature for 5 hr. After completion of the reaction, the mixture was extracted with ethyl acetate, and the extract was washed with saturated brine, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to give 8-methoxyacenaphthen-1-one (5.7 g). The obtained methoxy form was dissolved in methanol (25 ml), sodium borohydride (220 mg) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was gradually added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 8-methoxy-1-acenaphthenol (5.6 g). The title compound (2.28 g) was obtained according to the method of Example 125 and using the obtained alcohol form.
  • 1H-NMR (CDCl3) δTMS:1.65-1.95 (m, 2H), 2.10-2.20 (m, 1H), 2.30-2.50 (m, 2H), 2.65-2.90 (m, 3H), 3.30-3.40 (m, 1H), 3.45-3.60 (m, 1H), 4.07 (s, 3H), 4.20-4.40 (m, 1H), 5.00-5.10 (m, 1H), 7.00-7.15 (m, 3H), 7.20-7.35 (m, 4H), 7.56 (d, 1H), 7.71 (d, 1H), 9.80-10.10 (brs, 1H)
  • FAB-MS (M+H)+:400
    • Example 134 2-{3-[1-(8-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound (1.4 g) was obtained according to the method of Example 104 and using 1-[1-(8-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (1.58 g).
  • 1H-NMR(CDCl3) δTMS:1.65-1.85 (m, 2H), 2.10-2.20 (m, 1H), 2.35-2.50 (m, 2H), 2.78 (d, 3H), 2.65-2.95 (m, 3H), 3.30-3.40 (m, 1H), 3.45-3.55 (m, 1H), 4.07 (s, 3H), 4.20-4.35 (m, 1H), 4.48 (s, 2H), 5.00-5.05 (m, 1H), 6.14 (brs, 1H), 7.00-7.15 (m, 3H), 7.20-7.40 (m, 4H), 7.57 (d, 1H), 7.72 (d, 1H)
  • FAB-MS (M+H)+:471
    • Example 135 1-[1-(8-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The title compound is obtained according to the method of Example 128 and using 1-[1-(8-methoxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 136 2-{3-[1-(8-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound is obtained according to the method of Example 104 and using 1-[1-(8-hydroxyacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 137 (R)-1-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • To a suspension of 60% sodium hydride (5.00 g) in toluene (250 ml) was added dropwise ethyl diethylphosphonoacetate (23.9 ml) under ice-cooling, and the mixture was stirred at room temperature for 1 hr. Then, a solution of 5-fluoro-3,4-dihydro-2H-naphthalen-1-one (18.0 g) in toluene (50 ml) was added dropwise, and the mixture was stirred at 80° C. for 3 hr. After cooling to room temperature, the reaction mixture was poured into ice water, and the mixture was extracted with toluene. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl (5-fluoro-3,4-dihydronaphthalen-1-yl)acetate (17.4 g).
  • To a solution of ethyl (5-fluoro-3,4-dihydronaphthalen-1-yl)acetate (16.4 g) in benzene (500 mL) was DDQ (2,3-dichloro-5,6-dicyanobenzoquinone)(21.5 g), and the mixture was stirred with heating for 3 hr. After cooling, the precipitated solid was dissolved in 1N sodium hydroxide, and the mixture was extracted with toluene. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate) to give ethyl (5-fluoronaphthalen-1-yl)acetate (5.66 g).
  • To a solution of ethyl (5-fluoronaphthalen-1-yl)acetate (5.96 g) in ethanol (50 mL) was added 1N sodium hydroxide (50 mL), and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure, the obtained residue was poured into water, and the mixture was washed with ethyl acetate. The aqueous layer was acidified with 1N hydrochloric acid, and extracted with chloroform, and the extract was washed with water and saturated brine, dried is over magnesium sulfate, and concentrated under reduced pressure to give (5-fluoronaphthalen-1-yl)acetic acid (4.34 g). The title compound was obtained according to the method of Example 103 and using (5-fluoronaphthalen-1-yl)acetic acid.
  • 1H-NMR (DMSO-d6) δTMS:1.56-1.68 (m, 2H), 2.27-2.59 (m, 5H), 2.95 (d, 1H), 3.39-3.45 (m, 2H), 4.11-4.13 (m, 1H), 4.91-4.94 (m, 1H), 6.92-7.00 (m, 4H), 7.22-7.48 (m, 4H), 7.59 (t, 1H), 7.72 (d, 1H)
  • FAB-MS (M+H)+:388
    • Example 138 (R)-2-{3-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound was obtained according to the method of Example 104 and using (R)-1-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
  • 1H-NMR (DMSO-d6) δTMS:1.62-1.72 (m, 2H), 2.29-2.62 (m, 9H), 2.95 (d, 2H), 3.30-3.40 (m, 1H), 3.40-3.55 (m, 2H), 4.10-4.30 (m, 1H), 4.41 (s, 2H), 4.92-4.95 (m, 1H), 7.01-7.06 (m, 4H), 7.29-7.48 (m, 4H), 7.61-7.56 (m, 1H), 7.72 (d, 1H), 8.07-8.08 (m, 1H),
  • FAB-MS (M+H)+:458
  • [α]D20=+32.2°
    • Example 139 (R)-1-[1-(6-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
  • The title compound is obtained according to the method of Example 103 and using 6-chloro-1-acenaphthenone.
    • Example 140 (R)-2-{3-[1-(6-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide
  • The title compound is obtained according to the method of Example 104 and using (R)-1-[1-(6-chloroacenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one.
    • Example 141 (R)-1-[1-acenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
  • (1) (R)-1-(1-Acenaphthen-1-yl)piperidin-4-one (2.5 g) was dissolved in ethanol (20 ml), and 2,3-diaminopyridine (1.1 g) was added. The solution was ice-cooled, and tetraisopropyl orthotitanate (3.5 g) was added. The mixture was stirred at room temperature for 3 hr, the reaction mixture was ice-cooled, and sodium borohydride (0.6 g) was added. The mixture was stirred at room temperature for 3 hr, the reaction mixture was poured into ice water, and the insoluble material was removed by filtration. The filtrate was extracted with chloroform, and the extract was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give (R)-N3-[1-(1-acenaphthen-1-yl)piperidin-4-yl]-pyridine-2,3-diamine (1.4 g) as a red-yellow powder.
  • 1H-NMR (CDCl3) δTMS:1.45-1.56 (m, 2H), 1.94-2.01 (m, 2H), 2.26 (m, 1H), 2.49 (m, 1H), 2.66 (m, 1H), 2.85 (m, 1H), 3.07-3.20 (m, 2H), 3.39 (m, 2H), 4.26 (brs, 1H), 4.91 (t, J=5 Hz, 1H), 6.63 (dd, J=5 Hz, 7.6 Hz, 1H), 6.74 (d, J=7.6 Hz, 1H), 7.27 (d, J=6.9 Hz, 1H), 7.43-7.52 (m, 3H), 7.56 (d, J=5 Hz, 1H), 7.61 (d, J=8.2 Hz, 1H), 7.68 (d, J=7.7 Hz, 1H)
  • (2) (R)-N3-[1-(1-Acenaphthen-1-yl)piperidin-4-yl]-pyridine-2,3-diamine (1.4 g) was dissolved in tetrahydrofuran (10 ml), 1,1′-carbonyldiimidazole (0.8 g) was added, and the mixture was stirred at room temperature for 5 hr. The reaction mixture was poured into water, and the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous ammonium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (1.3 g) as a yellow solid.
  • 1H-NMR (CDCl3) δTMS:1.78-1.85 (m, 2H), 2.26-2.46 (m, 3H), 2.54-2.60 (m, 1H), 2.81 (m, 1H), 3.02 (m, 1H), 3.43 (m, 2H), 4.38 (m, 1H), 4.99 (t, J=5.5 Hz, 1H), 6.99 (dd, J=5.3 Hz, 7.8 Hz, 1H), 7.30 (d, J=6.8 Hz, 1H), 7.45-7.55 (m, 4H), 7.63 (d, J=8.2 Hz, 1H), 7.71 (m, 1H), 8.04 (d, J=5.3 Hz, 1H), 10.34 (brs, 1H)
  • FAB-MS (M+H)+:371
  • [α]L=+48.44° (c1.0, chloroform)
    • Example 142 (R)-2-{1-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-imidazo[4,5-b]pyridin-3-yl}-N-methylacetamide
  • (R)-1-[1-(Acenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (1 g) was dissolved in DMF (30 ml). Sodium hydride (120 mg, 60%) was added, and the suspension was stirred at room temperature for 20 min. Ethyl bromoacetate (500 mg) was added, and the mixture was stirred for 2 hr. The reaction mixture was poured into ice water, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous ammonium chloride solution, dried over magnesium sulfate, and concentration to give ethyl (R)-2-{1-[1-(acenaphthen-1-yl)piperidin-4-yl]-1,2-dihydro-2-oxo-imidazo[4,5-b]pyridin-3-yl}acetate. 40% Methylamine-methanol solution (20 ml) was added, the mixture was stirred at room temperature for 2 hr, and the reaction mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (0.86 g) as a white powder.
  • 1H-NMR (CDCl3) δTMS:1.78-1.86 (m, 2H), 2.24-2.44 (m, 3H), 2.54 (m, 1H), 2.78 (m, 1H), 2.80 (d, J=4.7 Hz, 3H), 3.02 (m, 1H), 3.42 (d, J=5.4 Hz, 2H), 4.38 (m, 1H), 4.62 (s, 2H), 4.98 (t, J=5.4 Hz, 1H), 6.24 (brs, 1H), 7.02 (dd, J=5.2 Hz, 7.8 Hz, 1H), 7.30 (d, J=6.9 Hz, 1H), 7.45-7.55 (m, 4H), 7.63 (d, J=8.2 Hz, 1H), 7.71 (m, 1H), 8.03 dd, J=1.2 Hz, 5.2 Hz, 1H)
  • FAB-MS (M+H)+:442
  • [α]D 24=+42.16° (c1.0, chloroform)
    • Example 143 (R)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
  • The title compound was obtained as a white solid according to the method of Example 141 and using (R)-1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-one and 2,3-diaminopyridine.
  • 1H-NMR (CDCl3) δTMS:1.60-1.80 (m, 3H), 1.85-2.10 (m, 3H), 2.15-2.25 (m, 2H), 2.45 (m, 1H), 2.70-2.90 (m, 4H), 3.05 (m, 1H), 3.92 (m, 1H), 4.37 (m, 1H), 7.00-7.12 (m, 2H), 7.14 (dd, J=7.7, 7.8 Hz, 1H), 7.19 (dd, J=7.7, 7.8 Hz, 1H), 7.51 (d, J=7.8 Hz, 1H), 7.77 (d, J=7.7 Hz, 1H), 8.06 (d, J=5.4 Hz, 1H), 10.00 (brs, 1H)
  • FAB-MS (M+H)+:349
  • [α]D 24=+46.0° (c0.5, chloroform)
    • Example 144 (R)-2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-imidazo[4,5-b]pyridin-1-yl}-N-methylacetamide.fumarate
  • The title compound was obtained as a white powder by preparing an acetone solution of an amorphous form obtained in the same manner as Example 142 and using (R)-1-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one and treating the acetone solution with 1.1 equivalents of fumaric acid.
  • 1H-NMR (DMSO-d6) δTMS:1.60-1.75 (m, 3H), 1.82 (m, 1H), 1.85-2.00 (m, 2H), 2.10-2.30 (m, 2H), 2.35-2.55 (m, 2H), 2.57 (s, 3H), 2.60-2.90 (m, 3H), 3.02 (m, 1H), 3.90 (m, 1H), 4.33 (m, 1H), 4.41 (s, 2H), 6.62 (s, 2H), 7.02-7.25 (m, 4H), 7.65-7.75 (m, 2H), 7.94 (d, J=5.2 Hz, 1H), 8.08 (m, 1H)
  • FAB-MS (M+H)+:420
  • [α]D 24=+13.65° (c0.25, methanol)
    • Example 145 (R)-1-[1-(acenaphthen-1-yl)piperidin-4-yl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
  • (R)-1-[1-(Acenaphthen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (0.78 g) was dissolved in DMF (20 ml), 60% sodium hydride (90 mg) was added, and the suspension was stirred for 20 min. Then, methyl iodide (340 mg) was added, and the mixture was stirred at room temperature for 3 hr. The reaction mixture was poured into saturated aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (chloroform/methanol) to give the title compound (0.58 g) as a yellow powder.
  • 1H-NMR (CDCl3) δTMS:1.76-1.84 (m, 2H), 2.24-2.45 (m, 3H), 2.53-2.59 (m, 1H), 2.78 (m, 1H), 3.01 (m, 1H), 3.43 (m, 2H), 3.49 (s, 3H), 4.39 (m, 1H), 4.98 (t, J=5.5 Hz, 1H), 6.98 (dd, J=5.3 Hz, 7.8 Hz, 1H), 7.30 (d, J=6.8 Hz, 1H), 7.45-7.55 (m, 4H), 7.63 (d, J=8.2 Hz, 1H), 7.72 (m, 1H), 8.04 (d, J=5.3 Hz, 1H)
  • FAB-MS (M+H)+:385
  • [α]D 24=+45.29° (c0.6, chloroform)
    • Example 146 (R)-1-[1-(acenaphthen-1-yl)piperidin-4-yl]-3-ethyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one-2 hydrochloride
  • A crude product obtained in the same manner as Example 145 and using ethyl bromide (250 mg) was treated with 4N hydrochloric acid-ethyl acetate solution to give the title compound (150 mg) as a yellow solid.
  • 1H-NMR (DMSO-d6) δTMS:1.25 (t, J=7.2 Hz, 3H), 1.83 (m, 1H), 1.96 (m, 1H), 2.82 (m, 1H), 2.94 (m, 1H), 3.10 (m, 1H), 3.30 (m, 2H), 3.56 (m, 1H), 3.68-3.75 (m, 1H), 3.90 (q, J=7.2 Hz, 2H), 4.79 (m, 1H), 5.65 (m, 1H), 7.08 (m, 1H), 7.47 (m, 1H), 7.59 (m, 1H), 7.68 (m, 1H), 7.78 (m, 1H), 7.93 (m, 1H), 8.01 (m, 1H), 8.25-8.30 (m, 2H), 12.41 (brs, 1H)
  • FAB-MS (M+H)+:399
  • [α]D 24=+46.76° (c0.6, methanol)
    • Example 147 (R)-1-[1-(acenaphthen-1-yl)piperidin-4-yl]-3-(2-methoxyethyl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one
  • The title compound (670 mg) was obtained as a yellow powder according to the method of Example 145 and using 2-bromoethylmethylether (320 mg).
  • 1H-NMR (CDCl3) δTMS:1.77-1.85 (m, 2H), 2.26-2.44 (m, 3H), 2.53-2.59 (m, 1H), 2.78 (m, 1H), 3.01 (m, 1H), 3.35 (s, 3H), 3.42 (m, 2H), 3.76 (t, J=5.7 Hz, 2H), 4.18 (t, J=5.7 Hz, 2H), 4.39 (m, 1H), 4.98 (t, J=5.5 Hz, 1H), 6.97 (dd, J=5.3 Hz, 7.8 Hz, 1H), 7.30 (d, J=6.8 Hz, 1H), 7.45-7.55 (m, 4H), 7.63 (d, J=8.2 Hz, 1H), 7.71 (m, 1H), 8.04 (d, J=5.3 Hz, 1H)
  • FAB-MS (M+H)+:429
  • [α]D 24=+40.22° (c1.0, chloroform)
    • Example 148 (R)-1-[1-(acenaphthen-1-yl)piperidin-4-yl]-3-cyclopropylmethyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one.2 hydrochloride
  • The title compound (270 mg) was obtained as a yellow solid by treating a crude product obtained in the same manner as Example 145 and using 1-(bromomethyl)cyclopropane (310 mg) with 4N hydrochloric acid-ethyl acetate solution.
  • 1H-NMR (DMSO-d6) δTMS:0.38-0.47 (m, 4H), 1.24 (m, 1H), 1.83 (m, 1H), 1.97 (m, 1H), 2.85 (m, 1H), 2.95 (m, 1H), 3.13 (m, 1H), 3.32 (m, 2H), 3.57 (m, 1H), 3.69-3.75 (m, 3H), 3.96 (m, 1H), 4.78 (m, 1H), 5.66 (m, 1H), 7.08 (m, 1H), 7.47 (m, 1H), 7.59 (m, 1H), 7.68 (m, 1H), 7.78 (m, 1H), 7.93 (m, 1H), 8.01 (m, 1H), 8.25-8.30 (m, 2H), 12.42 (brs, 1H)
  • FAB-MS (M+H)+:425
  • [α]D 24=+38.58° (c0.7, methanol)
  • The structural formulas of the Example compounds of the present invention are shown in the following Tables.
  • TABLE 1
    Example
    No. Structural formula
    1
    Figure US20100120841A1-20100513-C00025
    2
    Figure US20100120841A1-20100513-C00026
    3
    Figure US20100120841A1-20100513-C00027
    4
    Figure US20100120841A1-20100513-C00028
  • TABLE 2
    Example
    No. Structural formula
    5
    Figure US20100120841A1-20100513-C00029
    6
    Figure US20100120841A1-20100513-C00030
    7
    Figure US20100120841A1-20100513-C00031
    8
    Figure US20100120841A1-20100513-C00032
  • TABLE 3
    Example
    No. Structural formula
    9
    Figure US20100120841A1-20100513-C00033
    10
    Figure US20100120841A1-20100513-C00034
    11
    Figure US20100120841A1-20100513-C00035
    12
    Figure US20100120841A1-20100513-C00036
  • TABLE 4
    Example
    No. Structural formula
    13
    Figure US20100120841A1-20100513-C00037
    14
    Figure US20100120841A1-20100513-C00038
    15
    Figure US20100120841A1-20100513-C00039
    16
    Figure US20100120841A1-20100513-C00040
  • TABLE 5
    Example No. Structural formula
    17
    Figure US20100120841A1-20100513-C00041
    18
    Figure US20100120841A1-20100513-C00042
    19
    Figure US20100120841A1-20100513-C00043
    20
    Figure US20100120841A1-20100513-C00044
  • TABLE 6
    Ex-
    am-
    ple
    No. Structural formula
    21
    Figure US20100120841A1-20100513-C00045
    22
    Figure US20100120841A1-20100513-C00046
    23
    Figure US20100120841A1-20100513-C00047
    24
    Figure US20100120841A1-20100513-C00048
  • TABLE 7
    Example No. Structural formula
    25
    Figure US20100120841A1-20100513-C00049
    26
    Figure US20100120841A1-20100513-C00050
    27
    Figure US20100120841A1-20100513-C00051
    28
    Figure US20100120841A1-20100513-C00052
  • TABLE 8
    Example No. Structural formula
    29
    Figure US20100120841A1-20100513-C00053
    30
    Figure US20100120841A1-20100513-C00054
    31
    Figure US20100120841A1-20100513-C00055
    32
    Figure US20100120841A1-20100513-C00056
  • TABLE 9
    Example No. Structural formula
    33
    Figure US20100120841A1-20100513-C00057
    34
    Figure US20100120841A1-20100513-C00058
    35
    Figure US20100120841A1-20100513-C00059
    36
    Figure US20100120841A1-20100513-C00060
  • TABLE 10
    Example No. Structural formula
    37
    Figure US20100120841A1-20100513-C00061
    38
    Figure US20100120841A1-20100513-C00062
    39
    Figure US20100120841A1-20100513-C00063
    40
    Figure US20100120841A1-20100513-C00064
  • TABLE 11
    Example No. Structural formula
    41
    Figure US20100120841A1-20100513-C00065
    42
    Figure US20100120841A1-20100513-C00066
    43
    Figure US20100120841A1-20100513-C00067
    44
    Figure US20100120841A1-20100513-C00068
    45
    Figure US20100120841A1-20100513-C00069
  • TABLE 12
    Example No. Structural formula
    46
    Figure US20100120841A1-20100513-C00070
    47
    Figure US20100120841A1-20100513-C00071
    48
    Figure US20100120841A1-20100513-C00072
    49
    Figure US20100120841A1-20100513-C00073
  • TABLE 13
    Example No. Structural formula
    50
    Figure US20100120841A1-20100513-C00074
    51
    Figure US20100120841A1-20100513-C00075
    52
    Figure US20100120841A1-20100513-C00076
    53
    Figure US20100120841A1-20100513-C00077
  • TABLE 14
    Example No. Structural formula
    54
    Figure US20100120841A1-20100513-C00078
    55
    Figure US20100120841A1-20100513-C00079
    56
    Figure US20100120841A1-20100513-C00080
    57
    Figure US20100120841A1-20100513-C00081
    58
    Figure US20100120841A1-20100513-C00082
  • TABLE 15
    Exam-
    ple No. Structural formula
    59
    Figure US20100120841A1-20100513-C00083
    60
    Figure US20100120841A1-20100513-C00084
    61
    Figure US20100120841A1-20100513-C00085
    62
    Figure US20100120841A1-20100513-C00086
  • TABLE 16
    Ex-
    am-
    ple
    No. Structural formula
    63
    Figure US20100120841A1-20100513-C00087
    64
    Figure US20100120841A1-20100513-C00088
    65
    Figure US20100120841A1-20100513-C00089
    66
    Figure US20100120841A1-20100513-C00090
  • TABLE 17
    Example No. Structural formula
    67
    Figure US20100120841A1-20100513-C00091
    68
    Figure US20100120841A1-20100513-C00092
    69
    Figure US20100120841A1-20100513-C00093
    70
    Figure US20100120841A1-20100513-C00094
  • TABLE 18
    Example
    No. Structural formula
    71
    Figure US20100120841A1-20100513-C00095
    72
    Figure US20100120841A1-20100513-C00096
    73
    Figure US20100120841A1-20100513-C00097
    74
    Figure US20100120841A1-20100513-C00098
  • TABLE 19
    Example No. Structural formula
    75
    Figure US20100120841A1-20100513-C00099
    76
    Figure US20100120841A1-20100513-C00100
    77
    Figure US20100120841A1-20100513-C00101
    78
    Figure US20100120841A1-20100513-C00102
  • TABLE 20
    Ex-
    ample
    No. Structural formula
    79
    Figure US20100120841A1-20100513-C00103
    80
    Figure US20100120841A1-20100513-C00104
    81
    Figure US20100120841A1-20100513-C00105
    82
    Figure US20100120841A1-20100513-C00106
  • TABLE 21
    Example No. Structural formula
    83
    Figure US20100120841A1-20100513-C00107
    84
    Figure US20100120841A1-20100513-C00108
    85
    Figure US20100120841A1-20100513-C00109
    86
    Figure US20100120841A1-20100513-C00110
  • TABLE 22
    Example No. Structural formula
    87
    Figure US20100120841A1-20100513-C00111
    88
    Figure US20100120841A1-20100513-C00112
    89
    Figure US20100120841A1-20100513-C00113
    90
    Figure US20100120841A1-20100513-C00114
    91
    Figure US20100120841A1-20100513-C00115
  • TABLE 23
    Ex-
    am-
    ple No. Structural formula
    92
    Figure US20100120841A1-20100513-C00116
    93
    Figure US20100120841A1-20100513-C00117
    94
    Figure US20100120841A1-20100513-C00118
    95
    Figure US20100120841A1-20100513-C00119
    96
    Figure US20100120841A1-20100513-C00120
  • TABLE 24
    Example No. Structural formula
    97
    Figure US20100120841A1-20100513-C00121
    98
    Figure US20100120841A1-20100513-C00122
    99
    Figure US20100120841A1-20100513-C00123
    100
    Figure US20100120841A1-20100513-C00124
  • TABLE 25
    Example No. Structural formula
    101
    Figure US20100120841A1-20100513-C00125
    102
    Figure US20100120841A1-20100513-C00126
    103
    Figure US20100120841A1-20100513-C00127
    104
    Figure US20100120841A1-20100513-C00128
    105
    Figure US20100120841A1-20100513-C00129
  • TABLE 26
    Example No. Structural formula
    106
    Figure US20100120841A1-20100513-C00130
    107
    Figure US20100120841A1-20100513-C00131
    108
    Figure US20100120841A1-20100513-C00132
    109
    Figure US20100120841A1-20100513-C00133
    110
    Figure US20100120841A1-20100513-C00134
  • TABLE 27
    Example No. Structural formula
    111
    Figure US20100120841A1-20100513-C00135
    112
    Figure US20100120841A1-20100513-C00136
    113
    Figure US20100120841A1-20100513-C00137
    114
    Figure US20100120841A1-20100513-C00138
    115
    Figure US20100120841A1-20100513-C00139
  • TABLE 28
    Ex-
    ample
    No. Structural formula
    116
    Figure US20100120841A1-20100513-C00140
    117
    Figure US20100120841A1-20100513-C00141
    118
    Figure US20100120841A1-20100513-C00142
    119
    Figure US20100120841A1-20100513-C00143
    120
    Figure US20100120841A1-20100513-C00144
  • TABLE 29
    Example No. Structural formula
    121
    Figure US20100120841A1-20100513-C00145
    122
    Figure US20100120841A1-20100513-C00146
    123
    Figure US20100120841A1-20100513-C00147
    124
    Figure US20100120841A1-20100513-C00148
    125
    Figure US20100120841A1-20100513-C00149
  • TABLE 30
    Example No. Structural formula
    126
    Figure US20100120841A1-20100513-C00150
    127
    Figure US20100120841A1-20100513-C00151
    128
    Figure US20100120841A1-20100513-C00152
    129
    Figure US20100120841A1-20100513-C00153
    130
    Figure US20100120841A1-20100513-C00154
  • TABLE 31
    Ex-
    ample
    No. Structural formula
    131
    Figure US20100120841A1-20100513-C00155
    132
    Figure US20100120841A1-20100513-C00156
    133
    Figure US20100120841A1-20100513-C00157
    134
    Figure US20100120841A1-20100513-C00158
    135
    Figure US20100120841A1-20100513-C00159
  • TABLE 32
    Ex-
    ample
    No. Structural formula
    136
    Figure US20100120841A1-20100513-C00160
    137
    Figure US20100120841A1-20100513-C00161
    138
    Figure US20100120841A1-20100513-C00162
    139
    Figure US20100120841A1-20100513-C00163
    140
    Figure US20100120841A1-20100513-C00164
  • TABLE 33
    Ex-
    ample
    No. Structural formula
    141
    Figure US20100120841A1-20100513-C00165
    142
    Figure US20100120841A1-20100513-C00166
    143
    Figure US20100120841A1-20100513-C00167
    144
    Figure US20100120841A1-20100513-C00168
  • TABLE 34
    Ex-
    ample
    No. Structural formula
    145
    Figure US20100120841A1-20100513-C00169
    146
    Figure US20100120841A1-20100513-C00170
    147
    Figure US20100120841A1-20100513-C00171
    148
    Figure US20100120841A1-20100513-C00172
  • The pharmacological action of the compound of the present invention is explained in the following by way of Experimental Examples.
  • The comparison control compounds used were as shown below.
  • Compound A (WO2005/028466, cis or trans stereoisomer of compound 1)
    Compound B (WO2005/028466, the other stereoisomer of compound A)
  • Figure US20100120841A1-20100513-C00173
    • Experimental Example 1 ORL-1 Receptor-Binding Test (Experimental Method and Measurement)
  • Using a receptor membrane product prepared from HEK293 cell forcively expressing human ORL-1 receptor, a [3H]-nociceptin binding test was performed. To be specific, a test substance solution (50 μL) having various concentrations, a receptor product solution (900 μL) and a labeled ligand [3H]-nociceptin (50 μL) were successively added to a polypropylene tube and reacted at 25° C. for 60 min. The reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B. The filter was washed 3 times with ice-cooled 50 mmol/L HEPES buffer, and placed in a measurement vial. A liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka). The non-specific binding level was determined using an unlabeled ligand test compound A. The binding inhibitory rate (%) and inhibitory constant (Ki value) were calculated according to the following calculation formula.

  • binding inhibitory rate (%)={1−(B−N)/(T−N)}×100
  • N: non-specific binding level, T: total binding level, B: binding level in the presence of a test substance inhibitory constant (Ki value)=IC50/(1+L/Kd)
    IC50: 50% inhibitory concentration, L: labeled ligand concentration, Kd: dissociation constant of labeled ligand
    • Experimental Example 2 μ Receptor-Binding Test (Test Method and Measurement)
  • Using a receptor membrane product prepared from CHO cell forcively expressing human p receptor, a [3H]-DAMGO binding test was performed. To be specific, a test substance solution (50 μL) having various concentrations, a receptor product solution (900 μL) and a labeled ligand [3H]-DAMGO (50 μL) were successively added to a polypropylene tube and reacted at 25° C. for 60 min. The reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B. The filter was washed 3 times with ice-cooled 50 mmol/L Tris/HCl buffer, and placed in a measurement vial. A liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka). The non-specific binding level was determined using an unlabeled ligand test compound A. The binding inhibitory rate (%) and inhibitory constant (Ki value) were calculated according to the following calculation formula.

  • binding inhibitory rate (%)={1−(B−N)/(T−N)}×100
  • N: non-specific binding level, T: total binding level, B: binding level in the presence of a test substance inhibitory constant (Ki value)=IC50/(1+L/Kd)
    IC50: 50% inhibitory concentration, L: labeled ligand concentration, Kd: dissociation constant of labeled ligand
    • (Results and Discussion)
  • The results are shown in the following Table. The affinity (Ki value) in the above-mentioned experiments is shown with “+++” for not more than 10 nM, “++” for 10 nM-30 nM, “+” for 30 nM-100 nM, “−” for not less than 100 nM for inhibition, and ND shows no data is available.
  • TABLE 35
    Affinity Ki (nM)
    Test compound ORL-1 μ
    compound A +++ ++
    compound B +++ ++
    Example 2 +++ ND
    Example 4 +++ ND
    Example 8 +++ ND
    Example 16 +++ ND
    Example 79 +++ +
    Example 80 +++ −
    Example 103 +++ ND
    Example 104 +++ ND
    Example 108 +++ ND
    Example 110 +++ ND
  • As shown in the above-mentioned Table, the compounds of Examples 2, 4, 8, 16, 79, 80, 103, 104, 108 and 110 showed high affinity for ORL-1 receptor as evidenced by Ki value of 10 nM or lower.
  • Moreover, it was found that the compounds of Examples 79 and 80 have weak affinity for p receptor, and selectively act on ORL-1 receptor.
    • Experimental Example 3 Agonistic Action (Experimental Method and Measurement)
  • Using a receptor membrane product prepared from HEK293 cell forcively expressing human ORL-1 receptor, a GTPγ35S-binding test was performed. To be specific, a reaction buffer or a test substance solution (50 μL) having various concentrations, a reaction buffer (for total binding) or a GTPγS solution (for non-specific binding, final concentration: 10 μmol/L) (50 μL), a membrane solution (850 μL) and a GTPγ35S (Amersham Pharmacia Biotech) solution (final concentration: 100 μmol/L)(50 μL) were successively added to a polypropylene tube, and reacted at 30° C. for 60 min. The reaction mixture was filtered by suction in a cell harvester using a glass filter Whatman GF/B. The filter was washed 3 times with ice-cooled 50 mmol Tris/HCl buffer (pH 7.4), and placed in a measurement vial. A liquid scintillation cocktail ACS-II (Amersham) (2 mL) was added, and the radiation dose was measured by a liquid scintillation counter (LSC-5100, Aloka). Expressing the non-specific binding level with the addition of GTPγS as N, the binding level with the addition of a reaction buffer instead of a test substance as A and the binding level in the presence of a test substance as B, the agonistic activity, namely, GTPγ35S bound (%) is shown by the following calculation formula.

  • GTPγ35S bound (%)={(B−N)/(A−N)}×100
    • (Results and Discussion)
  • As shown in FIGS. 1-3, the compounds of Examples 2, 4, 8, 79, 80, 104 and 110 increased the proportion of GTPγ35S bound in a concentration-dependent manner. Thus, it has been clarified that the compounds of Examples 2, 4, 8, 79, 80, 104 and 110 act as agonists for ORL-1 receptor.
    • Experimental Example 4 Food Consumption Increasing Action in Rat (Experimental Method and Measurement)
  • It has been reported that administration of nociceptin, which is an endogenous agonist of ORL-1 receptor, into the brain ventricle of rat temporarily increases food consumption (NeuroReport 8: 369-371, 1996). Therefore, it is possible to measure in vivo ORL-1 receptor agonistic activity with an increase in the food consumption in rat as an index. When rat is housed in a 12 hr light-dark cycle, the rat ingests most food in the dark period. Therefore, the experiment was performed in the light period when rat generally rarely ingests food. To be specific, a test substance was orally administered at 3-4 hr after the start of the light period, and the food weight was measured at 1, 2, 4 and 6 hr after administration. The difference between the food weight immediately before administration and that after administration was taken as a food consumption amount, which was converted to the amount per 1 kg of the body weight of the rat.
    • (Results and Discussion)
  • The compounds of Examples 2, 4, 8, 79 and 80 significantly increase food consumption in rats. Thus, it has been clarified that these compounds act as ORL-1 receptor agonists in vivo.
    • Formulation Example 1 Tablet
  • compound of the present invention  10 mg
    crystalline cellulose 180 mg
    cornstarch 300 mg
    lactose 600 mg
    magnesium stearate  15 mg
  • The above-mentioned components are mixed according to a conventional method, and tableted by a conventional apparatus.
    • Formulation Example 2 Tablet
  • compound of the present invention 10.0 mg
    lactose 50.0 mg
    cornstarch 20.0 mg
    crystalline cellulose 29.7 mg
    polyvinylpyrrolidone K30  5.0 mg
    talc  5.0 mg
    magnesium stearate  0.3 mg
    120.0 mg 
  • The compound of the present invention, lactose, cornstarch and crystalline cellulose were mixed and kneaded using polyvinylpyrrolidone K30 paste, and the mixture was passed through a 20 mesh sieve to give granules. After drying at 50° C. for 2 hr, the granules were passed through a 24 mesh sieve, mixed with talc and magnesium stearate, and tablet weighing 120 mg per tablet was produced using a pestle with diameter 7 mm.
    • INDUSTRIAL APPLICABILITY
  • Compound (1) of the present invention has superior metabolic stability and strong ORL-1 receptor agonistic action, and can be used for the prophylaxis and/or treatment of diseases relating to ORL-1 receptors, such as central nervous system diseases (e.g., anxiety and stress disorder, melancholia, traumatic injury, Alzheimer's disease, dementia, sleep disorder, drug addiction, alcoholism), acute and/or chronic pain symptom, arterial blood pressure disorder and eating disorders such as obesity and anorexia.
  • This application is based on patent application Nos. 2007-051842, 2007-059260, 2007-078845 and 2007-093846 filed in Japan, the contents of which are incorporated in full herein by this reference. In addition, the patent documents and non-patent documents cited in the present specification are hereby incorporated in their entireties by reference, to the extent that they have been disclosed in the present specification.

Claims (11)

1. A compound represented by the formula (I)
Figure US20100120841A1-20100513-C00174
is one of
Figure US20100120841A1-20100513-C00175
m and n are the same or different and each is an integer of 1 to 3;
R1 is hydrogen,
lower alkyl,
lower alkenyl,
—C(O)-lower alkyl,
—C(O)O-lower alkyl,
—C(O)-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, lower alkyl-carboxyl,
lower alkyl-C(O)-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy,
lower alkyl-C(O)O-lower alkyl,
lower alkenyl-C(O)O-lower alkyl,
lower alkyl-O-lower alkyl,
lower alkyl-C(O)—NR3R4,
—S(O)2-lower alkyl,
—S(O)2-phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, lower alkyl-S-lower alkyl,
lower alkyl-S(O)-lower alkyl,
lower alkyl-S(O)2-lower alkyl,
lower alkyl-S(O)—NR3R4,
lower alkyl-NR3R4,
lower alkyl-NR5—C(O)-lower alkyl,
phenyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy, or benzyl wherein the phenyl is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
R3 and R4 are the same or different and each is hydrogen, lower alkyl which is optionally substituted by C3-7 cycloalkyl, cycloalkyl or lower alkenyl, or R3 and R4 in combination optionally form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy;
R5 is hydrogen, lower alkyl or lower alkenyl;
R2 is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, nitro, amino or cyano;
Ra and Rb are the same or different and each is hydrogen, lower alkyl, halogen, lower alkoxy, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, amino, alkanoylamino or cyano, provided that when
Figure US20100120841A1-20100513-C00176
is (c), either Ra or Rb is a group other than hydrogen;
X is O or S;
Y is CH2, O(CH3)2, O, S, SO or SO2; and
Z is CH or N, provided that when
Figure US20100120841A1-20100513-C00177
is (b), m is 2, n is 2, Y is CH2 and X is O,
then R1 is a group other than hydrogen, lower alkyl, —C(O)— lower alkyl and —C(O)O-lower alkyl,
or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein R2 is hydrogen and X is O, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein R1 is lower alkyl-C(O)—NR3R4 (one of R3 and R4 is hydrogen) or lower alkyl-C(O)—NR3R4 (R3 and R4 in combination form, together with the adjacent nitrogen atom, saturated nitrogen-containing heterocycle which is optionally substituted by lower alkyl, halogen, lower alkoxy, phenoxy or benzyloxy),
or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 which is selected from
2-{3-[1-(1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-(3-(1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl)-N-methylacetamide,
1-(4-fluoro-1-indan-1-ylpiperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one,
2-{3-(4-methyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-(3,3-dimethyl-1-indan-1-ylpiperidin-4-yl)-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(2,3,3a,4,5,6-hexahydrobenzo[de]chromen-6-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(1,2,2a,3,4,5-hexahydroacenaphthylen-5-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
1-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one,
2-{3-[1-(6-fluoro-1,2,2a,3,4,5-hexahydroacenaphthylen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(3-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(8-chloroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-methoxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
2-{3-[1-(5-hydroxyacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, and
2-{3-[1-(6-fluoroacenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide,
or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
5. A drug for the prophylaxis and/or treatment of a disease relating to an ORL-1 receptor, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
6. A drug for the prophylaxis and/or treatment of a central nervous system disease relating to an ORL-1 receptor, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
7. A drug for the prophylaxis and/or treatment of a central nervous system disease, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
8. A drug for the prophylaxis and/or treatment of a sleep disorder, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
9. A drug for the prophylaxis and/or treatment of alcoholism, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
10. A drug for the prophylaxis and/or treatment of drug addiction, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
11. A drug for the prophylaxis and/or treatment of anxiety and stress disorder, comprising the compound (I) of claim 1, or a racemic mixture thereof, or a corresponding enantiomer thereof or a pharmaceutically acceptable salt thereof.
US12/449,874 2007-03-01 2008-02-28 Benzimidazole compound and pharmaceutical use thereof Active 2029-11-20 US8877779B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
JP051842/2007 2007-03-01
JP2007-051842 2007-03-01
JP2007051842 2007-03-01
JP2007-059260 2007-03-08
JP2007059260 2007-03-08
JP059260/2007 2007-03-08
JP2007078845 2007-03-26
JP2007-078845 2007-03-26
JP078845/2007 2007-03-26
JP2007-093846 2007-03-30
JP2007093846 2007-03-30
JP093846/2007 2007-03-30
PCT/JP2008/053524 WO2008105497A1 (en) 2007-03-01 2008-02-28 Benzimidazole compound and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
US20100120841A1 true US20100120841A1 (en) 2010-05-13
US8877779B2 US8877779B2 (en) 2014-11-04

Family

ID=39721321

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/449,874 Active 2029-11-20 US8877779B2 (en) 2007-03-01 2008-02-28 Benzimidazole compound and pharmaceutical use thereof

Country Status (11)

Country Link
US (1) US8877779B2 (en)
EP (1) EP2128154B1 (en)
JP (2) JP5313865B2 (en)
KR (1) KR101165504B1 (en)
CN (1) CN101622241B (en)
AU (1) AU2008219980B2 (en)
BR (1) BRPI0808025A2 (en)
CA (1) CA2679530C (en)
ES (1) ES2541133T3 (en)
MX (1) MX2009009355A (en)
WO (1) WO2008105497A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216726A1 (en) * 2007-08-31 2010-08-26 Purdue Pharma L.P. Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
US20110178090A1 (en) * 2008-07-21 2011-07-21 Fuchino Kouki Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US20110178128A1 (en) * 2008-09-16 2011-07-21 Sumie Sekiguchi Benzimidazole compound in crystal form and salt thereof
US20110295013A1 (en) * 2009-02-03 2011-12-01 Hiroshi Iwamura Process for preparing 1-(4-piperidinyl)benzimidazolone derivatives
US10246465B2 (en) 2014-06-02 2019-04-02 Laboratorios Del Dr. Esteve S.A. Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain
US10703765B2 (en) 2014-06-02 2020-07-07 Esteve Pharmaceuticals, S.A. Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US10927128B2 (en) 2015-11-16 2021-02-23 Esteve Pharmaceuticals. S.A. Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US11058674B2 (en) 2016-11-28 2021-07-13 Mitsubishi Tanabe Pharma Corporation Drug for treating ***e addiction or preventing recurrence of same
US11236110B2 (en) 2017-10-17 2022-02-01 Esteve Pharmaceuticals, S.A. Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
JP6146164B2 (en) * 2013-06-28 2017-06-14 三菱瓦斯化学株式会社 A novel aldehyde having a tetralin skeleton and a method for producing the same.
TW201607923A (en) 2014-07-15 2016-03-01 歌林達有限公司 Substituted azaspiro (4.5) decane derivatives

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043366A (en) * 1997-12-05 2000-03-28 Hoffman-La Roche Inc. 1,3,8,-triaza spiro (4,5)decan-4-on derivatives
US6071925A (en) * 1997-01-30 2000-06-06 Hoffmann-La Roche Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives
US6075034A (en) * 1998-06-12 2000-06-13 Hoffmann-La Roche Inc. Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives
US6258825B1 (en) * 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6423725B1 (en) * 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
US20020128288A1 (en) * 1999-12-06 2002-09-12 Donald Kyle Benzimidazole compounds having nociceptin receptor affinity
US20030069249A1 (en) * 2001-04-18 2003-04-10 Qun Sun Nociceptin analogs
US20030176701A1 (en) * 1998-06-12 2003-09-18 Geo Adam Di-or triaza-spiro [4,5] decane derivatives
US20050070528A1 (en) * 2003-09-25 2005-03-31 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
US20050119308A1 (en) * 2002-03-29 2005-06-02 Koji Teshima Remedy for sleep disturbance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29137A (en) * 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
WO2000006546A1 (en) 1998-07-30 2000-02-10 The Picower Institute For Medical Research Immunotherapeutic anti-cancer pharmaceutical compositions
US20030226657A1 (en) * 2002-04-01 2003-12-11 Wallace Thomas E. Food delivery system and method for storing and heating food to a serving temperature
CN1856485A (en) * 2003-09-25 2006-11-01 索尔瓦药物有限公司 Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
DE102004030290A1 (en) 2004-06-23 2006-01-19 Siemens Ag Establishing a connection for the exchange of data of an IP-based service
JP4122015B2 (en) 2005-08-19 2008-07-23 株式会社日本水処理技研 Plant cleaning method, asbestos removal method and dismantling treatment method
JP2007059260A (en) 2005-08-25 2007-03-08 Toshiba Lighting & Technology Corp Illumination device and illumination fixture
JP4551848B2 (en) 2005-09-12 2010-09-29 シャープ株式会社 Developing device and image forming apparatus having the same
JP2007093846A (en) 2005-09-28 2007-04-12 Sanyo Epson Imaging Devices Corp Electro-optic device and electronic equipment

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071925A (en) * 1997-01-30 2000-06-06 Hoffmann-La Roche Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives
US6258825B1 (en) * 1997-05-30 2001-07-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
US6043366A (en) * 1997-12-05 2000-03-28 Hoffman-La Roche Inc. 1,3,8,-triaza spiro (4,5)decan-4-on derivatives
US6423725B1 (en) * 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
US6642247B2 (en) * 1998-06-12 2003-11-04 Hoffman-La Roche Inc. Di-or triaza-spiro [4,5] decane derivatives
US20030176701A1 (en) * 1998-06-12 2003-09-18 Geo Adam Di-or triaza-spiro [4,5] decane derivatives
US6075034A (en) * 1998-06-12 2000-06-13 Hoffmann-La Roche Inc. Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US20020128288A1 (en) * 1999-12-06 2002-09-12 Donald Kyle Benzimidazole compounds having nociceptin receptor affinity
US20060264638A1 (en) * 1999-12-06 2006-11-23 Euro-Celtique S.A. Benzimidazole compounds having nociceptin receptor affinity
US7456198B2 (en) * 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
US20030069249A1 (en) * 2001-04-18 2003-04-10 Qun Sun Nociceptin analogs
US20050119308A1 (en) * 2002-03-29 2005-06-02 Koji Teshima Remedy for sleep disturbance
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US20050070528A1 (en) * 2003-09-25 2005-03-31 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Cai et al. "Antagonists of the orxin....." Expert Opin. ther. Patents 16(5) p.631-646 (2006) *
Federal Registry "examination guidelines...." p.1-34 (2011) *
Hennessy et al. "Discovery of eminopiperidine....." CA156:327884 (2012) *
Lang et al. "Structure activit...." J. Med. Chem. v.47, p.1153-116- (2004) *
Nakano et al. "preparation of ......" CA149:332331 (2008) *
Patani et al. "Bioisoterism....." Chem. Rev. v. 96, p.3147-3176 (1996) *
Smart et al. "Orexins...." Eur. J. Pharm. v. 440, p.199-212 (2002) *
Smith et al. "Evidence implicating a role....." Neuroscience Lett. v. 341, p.256-258 (2003) *
Taheri et al. "The role of hypcretins....." Ann, Rev. Neurosci. v.25, p.283-313 (2002) *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US20100216726A1 (en) * 2007-08-31 2010-08-26 Purdue Pharma L.P. Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
US9527840B2 (en) 2007-08-31 2016-12-27 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9278967B2 (en) 2007-08-31 2016-03-08 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9890164B2 (en) 2008-07-21 2018-02-13 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US11111246B2 (en) 2008-07-21 2021-09-07 Purdue Pharma L.P. Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds
US9145408B2 (en) 2008-07-21 2015-09-29 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US20110178090A1 (en) * 2008-07-21 2011-07-21 Fuchino Kouki Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US8476271B2 (en) 2008-07-21 2013-07-02 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US10519156B2 (en) 2008-07-21 2019-12-31 Purdue Pharma L.P. 9′-Aza[3,9′-bi(bicyclo[3.3.1]nonan)]-3′-one and preparation thereof
US8471032B2 (en) 2008-09-16 2013-06-25 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound in crystal form and salt thereof
US20110178128A1 (en) * 2008-09-16 2011-07-21 Sumie Sekiguchi Benzimidazole compound in crystal form and salt thereof
US20110295013A1 (en) * 2009-02-03 2011-12-01 Hiroshi Iwamura Process for preparing 1-(4-piperidinyl)benzimidazolone derivatives
US10246465B2 (en) 2014-06-02 2019-04-02 Laboratorios Del Dr. Esteve S.A. Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US10703765B2 (en) 2014-06-02 2020-07-07 Esteve Pharmaceuticals, S.A. Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
US10689398B2 (en) 2015-10-23 2020-06-23 Esteve Pharmaceuticals, S.A. OXA-Diazaspiro compounds having activity against pain
US10927128B2 (en) 2015-11-16 2021-02-23 Esteve Pharmaceuticals. S.A. Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US11649248B2 (en) 2015-11-16 2023-05-16 Esteve Pharmaceuticals, S.A. Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US11058674B2 (en) 2016-11-28 2021-07-13 Mitsubishi Tanabe Pharma Corporation Drug for treating ***e addiction or preventing recurrence of same
US11236110B2 (en) 2017-10-17 2022-02-01 Esteve Pharmaceuticals, S.A. Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one

Also Published As

Publication number Publication date
JP5313865B2 (en) 2013-10-09
WO2008105497A1 (en) 2008-09-04
JPWO2008105497A1 (en) 2010-06-03
BRPI0808025A2 (en) 2014-06-24
JP2013107910A (en) 2013-06-06
AU2008219980A1 (en) 2008-09-04
KR20090115976A (en) 2009-11-10
AU2008219980B2 (en) 2012-01-12
MX2009009355A (en) 2009-09-11
EP2128154A4 (en) 2011-01-26
US8877779B2 (en) 2014-11-04
EP2128154B1 (en) 2015-04-08
CN101622241A (en) 2010-01-06
KR101165504B1 (en) 2012-07-13
ES2541133T3 (en) 2015-07-16
EP2128154A1 (en) 2009-12-02
CA2679530C (en) 2012-09-25
CA2679530A1 (en) 2008-09-04
CN101622241B (en) 2013-05-22

Similar Documents

Publication Publication Date Title
US8877779B2 (en) Benzimidazole compound and pharmaceutical use thereof
TWI314931B (en) Cgrp receptor antagonists
JP4357965B2 (en) Heteroaryl-substituted pyrrole modulators of metabotropic glutamate receptor-5
JP4299139B2 (en) Heteroaryl-substituted triazole modulators of metabotropic glutamate receptor-5
JP5982397B2 (en) FAAH inhibitor
JP5290964B2 (en) Novel 1,4-diaza-bicyclo [3.2.2] nonyloxadiazolyl derivatives and their medical use
US7754882B2 (en) Hexahydro-pyrrolo-isoquinoline compounds
US9156840B2 (en) D2 antagonists, methods of synthesis and methods of use
WO2001027104A1 (en) Substituted imidazolidinone derivatives
TW200843756A (en) Benzimidazole derivatives and methods of use thereof
TW200810752A (en) Modulators of muscarinic receptors
TWI444376B (en) Prolinamide pyridine compounds, pharmaceutical composition and medical use thereof
ZA200700321B (en) Kynurenic acid amide derivatives as NR2B receptor antagonists
JP4356453B2 (en) 4-Oxoimidazolidine-2-spiropiperidine derivatives
JP2004501136A (en) Amidine derivatives as selective antagonists of the NMDA receptor
JP2007506709A (en) Benzimidazolone and quinazolinone derivatives as agonists for the human ORL1 receptor
JP2010514672A (en) Fused heterocyclic compounds having CRF antagonist activity
WO2007097276A1 (en) Pyrrole derivative or salt thereof
JP2007533713A (en) N- [4-4 (4-morpholinyl) phenyl]-[(4-piperidinyl) methyl] carboxamide derivatives and their use as glycine transporter inhibitors
US20070197603A1 (en) Substituted indole ligands for the orl-1 receptor
RU2451017C2 (en) Benzimidazole compound and pharmaceutical use thereof
JP2023522078A (en) 1,5-dihydro-2,4-benzodiazepin-3-one derivatives and uses thereof
KR20070091009A (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
US8344000B2 (en) Compounds which have activity at M1 receptor and their uses in medicine
JP2004511487A (en) Pyrrole-condensed morphinoid derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: MITSUBISHI TANABE PHARMA CORPORATION,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKANO, MASAKAZU;MINOGUCHI, MASANORI;HANANO, TOKUSHI;AND OTHERS;REEL/FRAME:023188/0248

Effective date: 20090617

Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKANO, MASAKAZU;MINOGUCHI, MASANORI;HANANO, TOKUSHI;AND OTHERS;REEL/FRAME:023188/0248

Effective date: 20090617

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8